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Abstract
Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable 
successes in some cancers; however, significant problems remain with this approach. Many 
targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse 
after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor 
therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., 
pathways that are not reliant upon the same mechanisms as those which have been targeted). To 
address these limitations, an international task force of 180 scientists was assembled to explore the 
concept of a low-toxicity “broad-spectrum” therapeutic approach that could simultaneously target 
many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor 
microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary 
teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in 
total) that could be modified to improve patient outcomes. For these targets, corresponding low-
toxicity therapeutic approaches were then suggested; many of which were phytochemicals. 
Proposed actions on each target and all of the approaches were further reviewed for known effects 
on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic 
effects were found for 3.9% of the relationships between targets and hallmarks, and mixed 
evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of 
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the relationships revealed potentially complementary effects, and the remainder had no known 
relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had 
complementary relationships. These results suggest that a broad-spectrum approach should be 
feasible from a safety standpoint. This novel approach has potential to help us address disease 
relapse, which is a substantial and longstanding problem, so a proposed agenda for future research 
is offered.
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1. Introduction
Cancer is a source of significant and growing mortality worldwide, with an increase to 19.3 
million new cancer cases per year projected for 2025. More than half of cancer cases and 
mortality occur in low- and middle-income countries, and these proportions are expected to 
increase by 2025 [1]. Current treatments for cancer include surgery, radiotherapy and 
systemic treatments comprising cytotoxic chemotherapy, hormonal therapy, immunotherapy, 
and targeted therapies [2]. Cancer continues to stymie clinical treatment efforts, however, 
and the search for effective therapies continues.
This capstone paper describes the methods and results of a substantial effort by a large 
international group of biochemical and medical researchers, operating under the name of 
“The Halifax Project,” sponsored by a non-profit organization, Getting To Know Cancer. It 
summarizes and draws together material from a series of reviews on the hallmarks of cancer, 
presented in this special issue of Seminars in Cancer Biology, to present a conceptual 
framework for a new approach to cancer prevention and therapeutics. This approach involves 
the targeting of many specific high-priority anticancer mechanisms and pathways within a 
more comprehensive model of treatment and care. We refer to this as a “broad-spectrum” 
approach (i.e., an approach aimed at a broad spectrum of important mechanisms and 
pathways) [3]. The broad-spectrum approach involves combinations of multiple low-toxicity 
agents that can collectively impact many pathways that are known to be important for 
genesis and spread of cancer. By making extensive use of chemicals from plants and foods 
that have already been studied or utilized for cancer prevention and treatment, this approach 
offers a compelling rationale for addressing the underlying biology of cancer while being 
efficacious, non-toxic and cost-effective. We come together in the belief that a broad-
spectrum approach of this type, in the context of a therapeutic environment including 
conventional treatment and attentive to optimal health, would provide genuine benefit in 
clinical outcomes for cancer patients. In this paper we describe the rationale for broad-
spectrum therapeutics, detail the methods of the Halifax Project, summarize potential targets 
and agents related to eleven hallmark features of cancer, propose a research model for the 
development of broad-spectrum therapies, and call for action to advance this research model.
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1.1 Rationale for Broad-Spectrum Approach
Primary motivations for the development of a broad-spectrum approach stem from the 
distinct limitations that are evident in many current targeted therapies and the personalized 
medicine paradigm. Molecular target therapies represent a significant advance in the 
treatment of cancer. They include drugs such as imatinib, an inhibitor of the tyrosine kinase 
enzyme BCR-ABL, which has made chronic myelogenous leukemia a more manageable 
disease, and inhibitors of vascular endothelial growth factor receptor (VEGFR), such as 
sunitinib, sorafenib and bevacizumab, used in renal and colon cancers [2]. Other important 
treatments based on tumor-specific targets are now in use, including examples such as 
epidermal growth factor receptor (EGFR) inhibitors (gefitinib, erlotinib) used in lung cancer, 
and the Her2 inhibitor trastuzumab used in breast cancer. Another approach is the synthetic 
lethal model [4] exemplified by research on poly ADP ribose polymerase (PARP) inhibition, 
in which mutational loss of one or more redundant components of a cell survival pathway in 
tumorigenic cells confers selective sensitivity to drugs that target remaining pathway 
components.
These drugs target cells bearing one, or at most a few mutated gene products or other 
abnormalities not found on normal cells. In the therapeutic context, the action of the targeted 
agents can efficiently address malignant cells, without some of the effects on normal cells 
notorious in cytotoxic chemotherapy. This enables therapeutic responses and remissions. 
Over time, however, the genetic heterogeneity of tumors increases, engendering resistance to 
treatment. Resistant cells drive the emergence of increasingly aggressive disease, through 
clonal expansion and clonal evolution [Figure 1]. Epigenetic modifications, heritable cellular 
changes not caused by alterations to DNA sequences, but by alterations such as methylation 
of DNA or modification of the histone protein associated with DNA, may also affect patterns 
of gene expression and drive cancers [5]. Relapses often occur after only a few months, and 
tumors reappear, sometimes in exactly the same areas in which they originated [6]. 
Moreover, targeted agents are not without serious side effects, such as treatment-related 
mortality with bevacizumab and cardiopulmonary arrest with cetuximab. Meta-analysis of 
trials of recently approved cancer drugs including targeted therapies versus older drugs 
showed increased rates of grades 3 and 4 toxicity (OR=1.52), treatment discontinuation 
(OR=1.33) and toxic deaths (OR = 1.40) [7]. This worsening of adverse effects has gone in 
large part unacknowledged.
The efficacy shown to date with targeted therapies, aside from now-established treatments 
such as bevacizumab and trastuzumab, is nevertheless still limited. Sunitinib, for instance, 
extends overall survival by 4.6 months in renal cancer, compared with the previous treatment 
of interferon-ř[8]. While statistically significant, this degree of improvement is small 
comfort to afflicted patients, and challenges the extraordinary monetary investment in drug 
development as well as costs to the medical system that targeted therapies represent. The 
MOSCATO 01 trial of molecular triage was able to treat 25 of 111 patients with a variety of 
advanced cancers using therapies targeted to genomic alterations assessed from tumor 
biopsies [9]. Of these, 5 patients (20%) experienced partial response and 56% had stable 
disease. Based on the entire population of 111 patients, this is a partial response of less than 
5%, suggesting limited efficacy to date, an outcome also seen in some other studies. [10]. On 
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a more hopeful note however, a combination of pertuzumab with trastuzumab and the 
chemotherapy agent docetaxel was recently found to extend overall survival among the 
subset of breast cancer patients whose tumors express Her-2 by 15.7 months [11].
Interestingly, harnessing the body´s immune response against the tumor can also result in 
impressive durable clinical responses, perhaps because the immune system is a paragon of 
adaptability and can deal with changes in the mutational landscape of cancer to prevent 
escape from the therapeutic effect. Immunomodulatory antibodies recently licensed in the 
United states include ipilimumab as well as nivolumab and pembrolizumab, neutralizing two 
different inhibitory pathways that block antitumor T cell responses. These agents have 
achieved some successes in treating late stage cancers refractory to essentially any other 
treatments [12]. But even with these agents, response rates are still low and predicting who 
will respond is an unsolved challenge [13,14].
Many of these therapies are somewhat narrowly described as “personalized” because 
patients’  tumors must be tested for specific mutations to stratify patients to the correct 
therapy. Viewed in the larger context of individual biological variation, of course, specific 
mutations drive only the smallest degree of personalization. Truly personalized treatment 
approaches can be seen to include a much more comprehensive assessment of genetic and 
even lifestyle factors, such as nutritional, biobehavioral (stress management) strategies, and 
exercise habits, along with other host variables such as inflammation and immune status. 
Such an approach to personalizing treatment can be found in the systematic practice of 
integrative medicine, which played a significant role in the development of this model of 
broad-spectrum cancer therapy. Some definitions of integrative medicine stress simply the 
inclusion of complementary and alternative therapies alongside orthodox treatment [15]. A 
more relevant definition emphasizes a patient-centered, multi-intervention treatment 
paradigm that addresses the full range of physical, mental, emotional and environmental 
influences, utilizing an array of disciplines including diet, mind-body and physical activity 
therapies in addition to conventional therapies and dietary supplements to support optimal 
health [16], based on laboratory testing that enables comprehensive personalization.
The stratification of patients for these targeted and personalized therapies poses practical 
challenges. As indicated earlier, over 50% of the increase in cancer incidence by 2025 is 
projected to occur in the developing world [1]. As industrialization develops in lower-
income countries, occupational cancers are expected to increase, potentially aggravating this 
situation [17]. Cancer treatment in many of these countries is already becoming a social-
economic challenge due to the expense and medical infrastructure required [18], and the new 
generation of treatments may further strain local resources. Currently, the platforms used for 
testing to personalize regimens include whole exome or whole genome sequencing, whole 
transcriptome sequencing, and comparative genomic hybridization with still others in 
development. It is likely that such tests, and related expense, will proliferate in the future. 
Managing treatment toxicity is also a taxing and complex problem, as these toxicities 
necessitate additional medical interventions.
The expense of the new targeted therapies is also concerning. Eleven of twelve drugs 
approved by the US Food and Drug Administration (US FDA) in 2012 were priced above 
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$100,000 US per year per patient – perhaps not surprisingly in view of the accelerating costs 
of drug development [19]. Clinicians have drawn attention to these high costs: in 2013 more 
than 100 experts in chronic myeloid leukemia coauthored a paper calling for lower prices 
and broader access to these drugs [20]. The excessive costs have resulted in drugs not being 
approved for use by national or regional governments where cost-benefit analyses figure in 
approval processes [21]. While costs are expected to decrease after expiration of patents on 
the drugs, the costs for treatment in low- or middle-income countries may continue to be 
problematic. The potential for unsupportable financial stress on health systems challenges 
the research community to explore other treatment models that can be more sustainable in 
the face of the worldwide increase in cancer incidence.
The broad-spectrum approach that we describe here is primarily intended to address the two 
major issues of therapeutic resistance and cost. It is based on many of the insights of 
genomic sequencing in cancers. We now know that cancers harbor significant genetic 
heterogeneity, even within a single patient [6]. Based on this heterogeneity, cancers routinely 
evolve resistance to treatment through switching from one growth pathway to another [22]. 
The proposed strategy employs the basic principles of rational drug design, but aims to stem 
cancer growth by precisely targeting many growth pathways simultaneously. Some effort is 
now being made in combining targeted agents so that more than one pathway can be 
affected, but lack of therapeutic success, significant toxicity and costs make this a challenge 
[23–26].
We see the broad-spectrum approach as one that is complementary to existing therapies, 
preferably within the context of a genuinely integrative clinical system. Clinical situations in 
which such an approach might prove useful include (a) as a follow-up maintenance plan to 
conventional adjuvant treatment; (b) in situations of rare cancers and disease stages for 
which no accepted treatments exist; (c) for patients who do not tolerate conventional 
chemotherapy, hormonal therapy or targeted therapies; (d) for patients who experience 
relapse or progression after targeted treatment; (e) in hospice or palliative care patients 
where low- or non-invasive strategies are a legitimate and humane option; and (f) in 
situations in which high-cost agents cannot be obtained. Because of continuous 
heterogeneity among cancer cells, and their propensity for genomic instability, even a broad-
spectrum approach is unlikely to cause complete remission. However, the design of this 
approach posed a substantial theoretical challenge, for which we chose to use the hallmarks 
of cancer as a broad organizing framework.
1.2 Hallmarks of cancer as a framework for developing broad-spectrum therapeutics
Douglas Hanahan and Robert A. Weinberg first published their concept of the hallmarks of 
cancer in 2000 [27]. The hallmarks “constitute an organizing principle that provides a 
logical framework for understanding the remarkable diversity of neoplastic diseases.” This 
framework encompasses the biological capabilities that cells acquire during the development 
of cancers that allow them to become malignancies as we know them. Six hallmarks were 
proposed in the 2000 publication: sustained proliferative signaling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis and resisting cell death. The concept of the hallmarks became widely 
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recognized and influential. In 2011, Hanahan and Weinberg expanded on the initial 
hallmarks to include other areas of cancer biology that they felt were equally important [28]. 
They pointed out two enabling characteristics critical to the ability of cells to acquire the six 
hallmarks, and two new hallmark capabilities. They also singled out the crucial nature of the 
complex tumor microenvironment in the appearance of the cancer phenotype. The enabling 
characteristics are genomic instability and tumor-promoting inflammation; the new 
hallmarks are deregulating cellular energetics and avoiding immune destruction.
The hallmarks framework helps to define domains in which high priority targets can be 
identified for therapeutic targeting. Hanahan and Weinberg point out that agents are in 
development that target each of the hallmarks. They also note, however, that in response to 
targeted therapy, cancers may reduce their reliance on a particular hallmark capability, such 
as angiogenesis, and instead heighten the activity of another capability, such as invasion and 
metastasis [29]. This reaction has been clinically verified in the case of glioblastoma [30].
Another model, which was proposed by Vogelstein et al. in 2013 [6], also attempts to 
describe the mechanisms and pathways that are relevant to many cancers. In this model, 
“driver” genes that drive cancer growth are distinguished from “passenger” mutations found 
in cancer cells that impart no growth advantage. Twelve major signaling pathways that drive 
cancer growth have been elucidated, including signal transducers and activators of 
transcription (STAT), Notch, DNA damage control and 9 others. These pathways are 
classified into three cellular processes underlying tumor growth: cell survival, cell fate and 
genome maintenance. Individual patients with the same cancer can have mutations on 
different pathways, leading to inter-patient heterogeneity. Yet within each patient there is 
also substantial heterogeneity, both within each patient’ s primary tumor, and among and 
within metastases, with significance for treatment strategies. For instance, the smallest 
metastases visible through medical imaging may already have thousands of cells that harbor 
mutations rendering them resistant to current drugs [31].
Cancer mutations, moreover, are not simply a series of isolated targets. Beneath the surface 
of the cancer genome is a notably complex cellular signaling network, filled with 
redundancies. The elucidation of rational therapeutic combinations requires dynamic 
mechanistic models that reach beyond simple targeting [32]. What propels growth, 
dissemination and thus ineffective treatment and drug resistance actually appears not to be 
pathways acting in isolation but interconnected, multidirectional and dynamic networks [33]. 
Even sorafenib, which inhibits multiple kinases, is susceptible to the rapid development of 
resistance deriving from crosstalk in pathways such as phosphatidylinositide 3-kinase/
protein kinase B (PI3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-induced signaling or 
the epithelial-to-mesenchymal transition (EMT) [34]. Conventional drug discovery programs 
are now contemplating systems biology approaches aimed at furthering the network 
approach to pharmacology. The interdependence of cytokines, chemokines, growth factors, 
transcription factors, and their resulting proteomes, together with their relevance to cancer 
prevention and treatment [35], makes systems biology approaches most attractive [36]. This 
realization makes the significance of a broad-spectrum approach to cancer of even greater 
importance.
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Clinicians as well as researchers recognize the importance of heterogeneity in cancer. A 
least one clinical center recognizes the significance of this heterogeneity, and intervenes with 
broad-spectrum approaches to respond to it. In a 2009 book, Life Over Cancer, based on a 
clinic in operation since 1980, K.I. Block lays out a model of nutraceutical-based targeting 
of nine “pathways of progression” and six metabolic factors impacting the challenges faced 
by all cancer patients [3]. The nine growth pathways are proliferation, apoptosis, treatment 
resistance, immune evasion, angiogenesis, metastasis, cell-to-cell communication, 
differentiation and immortality. Multiple targeting of these pathways with natural products is 
used to simultaneously address multiple interconnected growth pathways. Comprehensive 
molecular profiling maps patients’  growth pathways and provides for relevant natural 
product intervention. The six metabolic “terrain factors” are oxidation, inflammation, 
glycemia, blood coagulation, immunity and stress chemistry. Terrain-focused interventions 
are tailored to patients’  laboratory test results, which are monitored regularly to guide 
therapeutic modification. Interventions include elimination of maladaptive lifestyle patterns, 
adjusting exercise habits, improving diet, implementing biobehavioral strategies to diminish 
adverse consequences of unabated stress/distress, and using natural products and 
medications that affect specific targets such as C-reactive protein (CRP) [37], interleukin-6 
(IL-6), nuclear factor Ţ-beta (NF-ŢB) [38], prostaglandin E2 and leukotriene B4 [39] for 
inflammation. Clinical observations and literature review suggest potential efficacy for this 
system in breast cancer (including a near-doubling of survival time of breast cancer patients 
in integrative care) and potentially other cancers [40,41]. Essentially, Block’ s clinical model 
systematically addresses multiple targets and pathways through a specific and selective 
broad-spectrum approach to treatment. While this system was developed in clinical practice, 
quite independently from the discussion of hallmarks and enabling characteristics by 
Hanahan and Weinberg, the conceptual overlap is obvious. That these concepts have already 
been used in clinical treatment provides powerful support for the viability of a carefully 
designed broad-spectrum approach.
The model we propose to use to develop a sound framework for a broad-spectrum approach 
recognizes these broad areas of conceptual overlap and agreement, and can be considered to 
best align with the hallmarks of cancer framework [27]. Our framework encompasses the 
molecular and metabolic diversity of malignancy recognized in Hanahan and Weinberg’ s 
hallmarks, Vogelstein’ s 12 growth pathways, Block’ s pathways of progression and terrain 
factors, and other emerging research. For the purposes of this project, we treat the 6 
hallmarks, 2 enabling characteristics, 2 emerging hallmarks, and the tumor 
microenvironment equally as hallmarks of malignancy. From a design standpoint, each of 
these individual areas encompasses an important aspect of cancer’ s biology, so each was 
seen as important to consider for a therapeutic approach aimed at a wide range of high 
priority targets.
In mid-2012, the framework for this project and approach were shared with Douglas 
Hanahan. He later independently provided support for this type of approach in a paper, 
“Rethinking the war on cancer” [42]. Using a military metaphor, he suggests a three-
dimensional cancer “battlespace” plan that attacks cancer in a full-scale war rather than 
individually targeted skirmishes. The first dimension is disruption of cancer’ s many 
capabilities, specifically those figuring in the hallmarks. Rather than just removing one 
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capability, as targeted therapies do, he explains that an ideal approach should target all the 
hallmark capabilities. The second dimension is defense against cancer’ s armed forces, 
implying specific targeting of the accessory cell types in the tumor microenvironment, such 
as tumor-promoting inflammatory cells. The third dimension represents the multiple 
battlefields of cancer: primary tumor, tumor microenvironment, lymph and blood vessels 
through which tumors disseminate, draining lymph nodes and distant organs. This 
dimension suggests still more targets.
A rapidly developing sub-discipline in oncology is the application of genetic and immune 
analysis of tumor tissue and the concomitant use of personalized therapies and prescriptions. 
These analyses allow better stratification of patients to treatments and clinical decision-
making [43]. In the case of breast cancer alone, tests range from Her-2 testing, the basis of 
trastuzumab treatment to sophisticated suites of tests that analyze dozens of genes. These 
complex analyses assist in treatment decisions based on correlations with clinical outcomes 
by predicting treatment response, risk of recurrence and outcome. They suggest the size of 
the network of genes that affect just one cancer, and emphasize the significance of a broad-
spectrum attack. Clinical utility of these tests is still under review [44].
Despite impressive progress in genomic and gene expression profiling, however, it is often 
impossible to fully characterize the range of immortalized cell variants within any given 
cancer. The perspectives offered by Hanahan Vogelstein and Block, as well as by the 
recognition of the network aspects of signaling pathways, however, suggest a larger number 
of targets may need to be reached. So the 138 driver genes, together with the 12 signaling 
pathways that comprise them, in addition to the molecular contributors to the hallmarks, and 
Block’ s nine pathways of progression and six terrain factors, help us delineate some of the 
most significant targets that should be taken into account in development of a broad-
spectrum approach.
2. Methods
The effort to develop the concept of broad-spectrum targeting of cancer through a complex 
combination of agents, emphasizing naturally occurring chemicals, was developed by a non-
profit organization, Getting To Know Cancer, and implemented within an initiative called 
“The Halifax Project.” The aim of the project was to produce a series of reviews of the 
cancer hallmarks that could collectively assess and prioritize the many target choices that 
exist, and also identify non-toxic chemicals (primarily from plants or foods) that could 
safely be combined to produce an optimized broad-spectrum approach that has both 
prophylactic and therapeutic potential. To that end, it was envisioned that eleven teams of 
researchers would produce reviews on the ten cancer hallmarks plus the tumor 
microenvironment, which was treated as a hallmark for the purposes of this project. Each 
review was to describe the hallmark, its systemic and cellular dysfunctions, and its 
relationships to other hallmarks. A priority list of relevant therapeutic targets and 
corresponding approaches suited to those targets was requested, along with a discussion of 
research needed in the context of goals of the project. Natural compounds were emphasized 
because of the growing body of literature that supports the low toxicity and interesting 
potential that many of these substances have demonstrated (i.e., as targeted therapeutics or in 
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cancer prevention), while recognizing the variable effectiveness of these compounds in 
human trials as well as the undocumented safety or frank toxicity concerns with many 
natural products [45].
In recognition of the network of signaling pathways involved not only in drug resistance but 
the interconnection and maintenance of all the hallmarks, the project implemented a cross-
validation step in the evaluation of targets and approaches. Because of the diversity of the 
targets involved in the 11 hallmark areas, it is not unreasonable to suspect that inhibiting or 
stimulating a target relevant to one hallmark may have an adverse growth effect or clinically 
adverse effect on a target in another hallmark. For instance, reducing DNA damage is a 
potential target for counteracting genomic instability. Activation of the immune system can 
counter DNA damage by eliminating damaged cells. However, activation of the immune 
system, while reducing overall levels of DNA damage, can contribute to chronic 
inflammation. [46].
Similar considerations apply to therapeutic approaches. For instance, triptolide, a component 
of the Chinese herb Tripterygium wilfordii, is known to cause apoptosis in cancer cells [47]. 
Extracts of the herb have been used in clinical trials for a variety of inflammatory and 
immune-linked conditions, and have demonstrated both antiinflammatory and immune 
suppressant activity, raising concern for its effect on immune evasion [48,49].
To address this issue, a specially designated cross-validation team was created within the 
project to evaluate all selected targets and approaches, i.e., to determine whether the 
inhibition or activation of targets, and the application of approaches, would have negative 
effects on other hallmarks. Each potential target-hallmark or approach-hallmark interaction 
was assessed to determine whether the pair had a complementary interaction (i.e., the 
interaction of the target or approach with the hallmark facilitated anticancer activity), a 
contrary interaction (i.e., the interaction of the target or approach with the hallmark had a 
potential adverse tumor-stimulating or tumor-progression effect), a controversial interaction 
(i.e., mixed indications of anticancer and tumor-stimulating effects), or no known 
relationship. A sample cross-validation table for dysregulated metabolism approaches can be 
accessed as Supplemental Table S1.
It is important to note that the cross-validation team was not given any restrictions for 
literature selection for this effort, and contributing authors were not restricted to cancer-
related research. This approach was taken because it was realized at the outset that this 
breadth and specificity of knowledge does not yet exist in the literature. As a result, the 
types and sources of data gathered in this effort varied considerably, although original 
studies were consistently favored over review articles. Moreover, many studies that were 
cited in this effort considered only a compound’ s ability to instigate or promote an action 
that mimics a hallmark phenotype in a manner directionally consistent with changes that 
have been associated with cancer. So while we refer to these as anticancer or tumor-
stimulating, the specificity of these activities and their implications for cancer treatment 
cannot and should not be immediately inferred from this database. In other words, the results 
from this aspect of the project were only compiled to serve as a starting point for future 
research, rather than a conclusive guide to therapy.
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Targets or approaches that have a substantial number of “contrary” assessments are less 
attractive for inclusion in the broad-spectrum approach. On the other hand, the use of targets 
and approaches that appear to have the potential for multiple complementary interactions is 
consistent with principles of rational drug design, and akin to efforts to design “dirty” drugs 
(a pharmacological term for drugs with multiple targets – as opposed to single targets -- 
aimed at multidimensional conditions) [50]. Further evaluation of such “dirty” targets and 
approaches could be undertaken through more specific application of network 
pharmacology, for which new tools are currently becoming available [51]. The tabulated 
results, which appear in the individual reviews, are discussed in a later section of this paper.
The review teams needed for the Halifax Project were formed by first circulating an email to 
a large number of cancer researchers, seeking expressions of their interest in participation. 
The email was circulated in July 2012 by Getting To Know Cancer, and scientists were 
encouraged to submit their details on a dedicated webpage that offered additional project 
detail. From the pool of 703 cancer scientists who responded to the email, 11 team leaders 
were selected to each lead a group in producing a review of each hallmark, and an additional 
leader selected for the cross-validation team. Those leaders were then asked to form their 
own teams (by drawing from the pool of researchers who expressed interest in the project, 
and from their own circles of collaborators). Ultimately, 12 teams were formed. Team 
members were each encouraged to engage a junior researcher as well. This led to fairly large 
teams but it allowed us to distribute the effort considerably. Team leaders all received project 
participation guidelines; extensive and ongoing communication from the project leader, 
Leroy Lowe; copies of the relevant papers of Hanahan and Weinberg; and copies of Life 
Over Cancer by Block [3] as an example of practical clinical implementation of the broad-
spectrum approach. In addition to the 11 teams, two guest editors, Anupam Bishayee and 
Keith Block, were selected for this special issue of Seminars in Cancer Biology in which the 
team reviews are published.
The team leaders and other team members who were able to attend the project workshop met 
in Halifax, Nova Scotia in August 2013 to discuss the project. Drafts of hallmark team 
papers were submitted in advance, and summary presentations made at the meeting. Other 
subject matter presentations included presentations on research funding in the natural 
products area (Jeffrey D. White, Office of Cancer Complementary and Alternative Medicine, 
National Cancer Institute) and the concept of driver and passenger genes (Bert Vogelstein, 
Johns Hopkins). Presentations on integrative cancer therapeutics made at the meeting are 
summarized below (Keith Block, Penny Block, Block Center for Integrative Cancer 
Treatment). Group discussions were held to facilitate communication among teams and 
project staff, and to assist teams in exploring the requirements and rationale for selection of 
targets and approaches.
Each hallmark team contained the following specialists: a lead author with demonstrated 
expertise in the hallmark area; domain experts who produced the descriptive review; 
anticancer phytochemical specialists; oncologists; and support researchers. The cross-
validation team conducted background literature searches on the submitted targets and 
compounds from each review team, verifying their activity in relation to the other hallmarks. 
Results of the cross-validation effort were tabulated and reviewed by the individual teams. 
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Ambiguous results and areas of disagreement were reconciled, and the tables were 
ultimately incorporated into each hallmark review.
2.1 Selection of targets and approaches
It was assumed from the outset that, in a translational project aimed at the development of a 
broad-spectrum approach, there would be a practical upper limit to the number of potential 
targets in any given cancer that could be targeted. So each hallmark team was asked to select 
and prioritize up to 10 relevant targets for their hallmark area, bearing in mind that each 
target would serve as a starting point for the identification of a suitable low-toxicity 
approach that might be used to reach that target. In theory, it was understood that this could 
lead to as many as 110 targets for the entire project, and since the teams were also asked to 
select one therapeutic approach for each target, a maximum of 110 potential therapeutic 
approaches might be selected.
An “approach” was defined in this project as (1) a technique that will cause the body to 
respond in a manner that will act on the target (e.g., fasting, exercise etc.), or (2) a procedure 
involving an entity that can act on the target (e.g., phytochemical, dietary modification, 
synthetic drug, vaccination with peptides, locally administered oncolytic virus etc). Teams 
were then asked to identify “favored” approaches with patient safety as a top priority (i.e., 
least likely to cause harm or side effects even in combination with many other approaches). 
In addition to safety, other practical considerations for choosing favored approaches were 
suggested as follows:
• Efficacy – Greatest potential to achieve the desired action on the intended target 
across the widest possible range of cancer types
• Cost – Less expensive is better, and by no means cost prohibitive
• Intellectual Property – Free of intellectual property constraints if at all possible.
Approaches that do not have patents, that cannot be patented, and/or those that have 
patents that are expired are to be given priority over those that have existing 
patents.
2.1.1 Selection of targets—Extensive discussion took place about the principles of 
target selection. Certainly targets that are unique to cancer cells and tumor 
microenvironments, and that are not known to cause side effects when inhibited 
pharmacologically, would be a primary consideration. Targets induced by viruses or known 
carcinogens that are of importance in therapy would also be examined. Consideration of the 
nature of mutations in the cancer genome and the role of epigenetic modification were also 
discussed.
It is understood that great effort has been made to sequence the cancer genome to identify 
the most common mutations seen in different cancers. It is also known that different driver 
mutations may give rise to variant tumor cells, and the number of driver mutations required 
is limited, with just 2–8 per patient, which could potentially be assessed through whole 
genome sequencing of individual cancer patients. However, questions arise about treatment, 
since most of the currently available drugs are not potent enough to target all susceptible 
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cells. Moreover, the toxicity of existing drugs, if administered in combination protocols, is 
severely limiting, even at the reduced dosages that may be possible when using multiple 
agents. A strong rationale supports focusing on low toxicity chemistry (e.g., such as that 
which has been demonstrated by many anticancer and chemopreventive phytochemicals as 
the foundation for a broad-spectrum approach. A number of phytochemicals enhance 
absorption of other natural products through such mechanisms as cytochrome P450 
modification [52], which could also enhance the possibilities for low-toxicity treatment, i.e., 
by reducing dosages needed for effective treatment.
Many driver genes are actually tumor suppressor genes, and in these cases, it is the loss of 
the tumor suppressor gene that allows development of cancer. Drugs cannot target these 
missing genes. Rather they must target unopposed pathways, such as pathways that are 
active upstream from the missing suppressor gene. For instance, the tumor suppressor 
forkhead box 0 (FOX0) normally causes apoptosis. If FOX0 is inactivated in cancer, an 
unopposed pathway upstream from it is the PI3K/Akt1 signaling pathway, which could 
alternatively be targeted [53]. The mitogen-activated protein kinase/extracellular-signal 
regulated kinase/mitogen/extracellular signal-regulated kinase (MEK) pathway, however, 
can act as a substitute or compensatory pathway to PI3K/Akt1. So, in order to effectively 
shut down replication, it would seem necessary to address these pathways as well.
Cancer-related signaling pathways, including even those that become driver pathways, may 
be epigenetically modified prior to their genetic modification in cancer pathogenesis [54]. 
This suggests an emphasis on chemoprevention or treatment of very early cancers. Targeting 
may be more straightforward to achieve under these conditions, since it is easier to modulate 
wildtype pathways pharmacologically than to treat the consequences of the onset of 
widespread aneuploidy. In this case, the cancer phenotype may well precede the cancer 
genotype by years or more. Combining knowledge of genetic and epigenetic changes in a 
particular tumor may result in the targeting of key pathways with fewer agents and reduced 
cost.
A more general consideration is that both direct and indirect targets and approaches can be 
considered. Direct targets are those that are familiar to us from targeted therapies – 
oncogenes, tumor suppressor genes, signaling pathways. Indirect approaches, however, are 
also potentially useful. For instance, evasion of the immune system is a hallmark of cancer 
[27], and immunomodulatory targets and approaches are appropriate to support the 
capacities of immune cells to eliminate tumor cells. Immune regulators are, in a sense, 
inherently multi-targeted due to the complexity of the responses they induce [55]. However, 
immunity is frequently compromised in patients under treatment with cytotoxic 
chemotherapies, as well as in the post-surgical period. Immune system approaches that also 
support the capacity of patients to tolerate or recover from surgery or toxic therapies 
indirectly support the health of cancer patients [56]. The potency of the immune system is 
illustrated by findings that chemotherapy may enhance antitumor immunity if given in the 
correct sequence, and that cancer refractory to chemotherapy or immune modulation alone 
may become susceptible to both together [57].
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2.1.2 Selection of approaches—The need for low-toxicity agents as constituents 
suggested that phytochemicals –especially those “pre-screened” in humans owing to their 
presence in foods or traditional medicines -- should be carefully considered during approach 
selection. Each hallmark team therefore included cancer researchers who had considerable 
experience working with phytochemicals. In considering phytochemicals and other low-
toxicity agents for inclusion in a broad-spectrum approach, however, several limitations in 
the literature promptly become clear.
First, the level of evidence for the effects of natural products on particular hallmark targets 
varies widely. The status of laboratory studies and clinical trials on several well-known 
phytochemicals, e.g. resveratrol, epigallocatechin gallate (EGCG), curcumin, lycopene and 
others, was recently reviewed [58]. The pleiotropic nature of the effects of these agents on 
apoptosis and arrest of cell growth has been emphasized, and their potential use in 
association with chemotherapy drugs has been acknowledged. Novel strategies based on a 
strategic combination of phytochemicals with broad-spectrum action together with radiation 
or chemotherapy agents aimed at overcoming resistance to apoptosis and enhancing 
sensitivity to treatment are also currently being considered [59,60].
Second, considerable clinical experience with combinations of phytochemicals and other 
natural agents in treatment of cancer patients exists. Detailed knowledge of the 
pharmacological effects of combinations of phytochemicals, however, is limited. There is a 
large literature on herbal combinations used in traditional Chinese medicine in both the 
laboratory and clinic [61–63], but the quality of older clinical trials is generally low. 
Additionally, laboratory studies of herbal medicines often use concentrations far higher than 
are clinically achievable. Supra-physiological concentrations can produce artefactual or 
irrelevant mechanisms of action or cause toxicity. The limited bioavailability of major 
phytochemicals makes this especially concerning, although products with improved 
bioavailability are in development [64]. In general, phytochemical research merits rigorous 
attention if we hope to gain a more detailed understanding of how these compounds affect 
the cancer hallmarks. Basic research needs to be followed up with better-designed, 
statistically powered clinical trials, if we hope to fully realize the therapeutic potential of 
phytochemicals.
In addition to laboratory studies and clinical trials, approaches may be suggested by 
epidemiological studies and the observations of integrative medicine, which uses diet and 
lifestyle therapies to affect medical conditions including cancer. Observational studies of soy 
consumption, along with corroborating evidence from clinical studies, suggest that dietary 
consumption of soy foods consistent with levels in the Japanese diet (2–3 servings daily, 
containing 25–50 mg isoflavones) may be associated with reduced risk of breast cancer 
incidence and mortality [65]. However, findings from animal studies [66] of negative effects 
of the soy isoflavone genistein on breast cancer and its treatment suggest some caution and 
avoidance of simplistic recommendations.
At all levels of investigation, the multi-targeted nature of phytochemicals as well as the 
integrative therapies is notable. Many isolated phytochemicals and herbals may alter large 
numbers of targets through multifaceted effects on physiology and metabolism [67–69]. A 
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basic complication of these multi-targeted agents, however, is the lack of mechanistic 
understanding and scientific acceptance of the roles of synergistic or additive molecules in 
formulation. Although used by human populations for millennia, there remains a question of 
how to develop and assess multi-component natural product formulations that are suitable 
for large-scale production. Genome-wide screening for assessment of targeted effects and 
experimentation with formulation of some herbs typical of traditional Ayurvedic medicine 
have recently been attempted in Asian laboratories, and are examples of attempts to better 
understand effects of multi-component agents [70–72].
3. Hallmarks of cancer
In this section we provide brief summaries of each hallmark review included in this special 
issue of Seminars in Cancer Biology. Each summary includes the targets and approaches 
selected in the hallmark review. Tables summarizing the targets and approaches and 
discussion of the cross-validation results follow. In addition, a summary of the impacts of 
integrative therapies on cancer-related molecular targets follows the hallmark summary 
material.
The hallmark summaries are roughly sequenced to capture the acquired capabilities of most 
cancers (see Figure 2). The section begins with genomic instability, an enabling 
characteristic, followed by sustained proliferative signaling and evasion of anti-growth 
signaling, two hallmarks that ensure that proliferation is unabated in cancer cells. These are 
followed by resistance to apoptosis and replicative immortality, two layers of defense that 
are believed to be bypassed in all cancers. Then we discuss dysregulated metabolism and 
tumor-promoting inflammation, which signal an important self-reinforcing evolution in the 
tumor microenvironment. Sections on angiogenesis and tissue invasion and metastasis speak 
to disease progression. Finally the tumor microenvironment and immune system evasion 
summaries relate to the last lines of defense to be defeated in most cancers.
3.1 Genomic instability
Genomic instability plays a critical role in cancer initiation and progression. It provides the 
means by which a cell or subset of cells acquire a selective advantage over neighboring cells, 
enabling outgrowth and dominance in the tissue microenvironment. In normal cells, the 
fidelity of the genome is protected at every stage of the cell cycle by checkpoints. In cancer, 
the presence of aneuploid cells indicates the failure of one or more of these checkpoints. The 
resulting genomic heterogeneity may offer the cancer “tissue” growth advantages under 
selective pressures, including hypoxia, immune- and therapy-related challenges. 
Understanding these checkpoints, and how they are bypassed in cancer cells, may provide 
opportunities for the development of rational combinatorial or broad-spectrum treatment 
strategies, including nutraceuticals such as resveratrol [73,74].
A cell, either transformed or normal, must pass through multiple checkpoints during the 
process of division. These checkpoints are operated by functional complexes of proteins that 
either enable the cell to pass through the checkpoint (e.g. proto- or oncogenes) or prevent the 
progression through the cell cycle (i.e. tumor suppressors). The abundance of these proteins, 
and their functionality, can be modified by genetic changes to their encoding sequences or 
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by non-genetic, or epigenetic, changes that regulate their abundance. Briefly, small changes 
to the genes that encode proto-oncogenes or tumor suppressors will positively or negatively 
impact the function of the gene products. These small changes can be induced by 
environmental and lifestyle factors, such as toxic substances, diet, and smoking, or they can 
be encoded in the individual at conception. In the case of DNA damage generated by the 
environment, it is important that the cell repairs the damage effectively. Dysfunction in the 
molecules that come together to recognize and respond to sites of damage is often associated 
with human cancer. Thus, an understanding of the genetic or epigenetic status of DNA repair 
genes, and of the nutraceuticals that may modulate them [75], provides an opportunity to 
predict, detect, prevent and treat a variety of human cancers.
Growing evidences show that vitamins, minerals, and other dietary factors have profound 
and protective effects against cancer cells, whether they are grown in the lab, in animals, or 
studied in human populations. We have identified five targets against genomic instability: (1) 
prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA 
repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity. 
Vitamins D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates 
are priority approaches against genomic instability; these approaches may dampen other 
enabling characteristics of tumor cells, such as replicative immortality, evasion of anti-
growth signaling, tumor promoting inflammation, and oncogenic metabolism [73,76–82].
3.2 Sustained proliferative signaling
Proliferation plays an important role in cancer development and progression, as manifested 
by altered expression and activity of proteins related to the cell cycle [83,84]. Constitutive 
activation of a large number of signal transduction pathways takes place in cancer; this also 
stimulates cell growth. Early in tumor development a fibrogenic response is often seen. 
Along with the development of a hypoxic environment [85,86], this favors the appearance 
and proliferation of cancer stem cells (CSCs). The survival strategies distinguishing CSCs 
from normal tissue stem cells involve lack of cellular differentiation and alterations in cell 
metabolism, such as higher antioxidant levels [83,84]. These alterations take place as cells 
adapt to the changing microenvironment in affected tissue, prior even to the appearance of 
tumors. A part of this adaptation embodies epigenetic and genetic alterations in gene 
expression [6,87] that also confer resistance to many cytotoxic treatments [88,89]. Thus, 
adaptive resistance is likely acquired early in the pathogenesis of many tumor types.
Once tumors appear, the continued selection of cells with sustained proliferative signaling 
further promotes tumor heterogeneity. This is accomplished by growth and metastasis, 
which may be supported by overproduction of appropriate hormones (in hormonally 
dependent cancers), by promoting angiogenesis, by undergoing EMT, by altering the balance 
between apoptosis, necrosis and autophagy, and by taking cues from surrounding stromal 
cells. A number of natural compounds (such as EGCG) have been found to inhibit one or 
more pathways that contribute to proliferation [90–92]. Many of these compounds are 
nontoxic at doses that inhibit tumor growth and/or prevent the appearance of tumor. 
However, one of the keys to their efficacy involves their earliest possible therapeutic 
application. This is because their efficacy is likely to be the greatest in target tissues prior to 
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the appearance of a tumor where cellular heterogeneity is the least. In addition, many of the 
steps in carcinogenesis prior to tumor appearance are epigenetic in nature, and are more 
easily targeted by existing compounds, most of which target wild type molecules. This 
approach limits adaptive resistance, since early intervention does not have to deal with the 
issues of aneuploidy, loss of heterozygosity in multiple tumor suppressor genes, and point 
mutations in oncogenes. The contribution of bioinformatics analyses will be important for 
identifying signaling pathways and molecular targets that may provide early diagnostic 
markers and/or critical targets for the development of new drugs or combinations that block 
tumor formation. Thus, early intervention in pathways and molecules that mediate sustained 
proliferative signaling will limit adaptive resistance because it targets cells in tissues that 
have limited genotypic and phenotypic heterogeneity.
Targets selected for sustained proliferative signaling are hypoxia-inducible factor-1 (HIF-1) 
signaling, NF-ŢB signaling, PI3K/Akt signaling, wingless-type mouse mammary tumor 
integration site (Wnt) (Ś-catenin) signaling, insulin-like growth factor receptor (IGF-1R) 
signaling, cell cycle [cyclin-dependent kinases (CDKs)/cyclins], androgen receptor 
signaling, and estrogen receptor signaling. Possible therapeutic approaches include 
curcumin, genistein and resveratrol.
3.3 Evasion of Anti-growth Signaling
Normal cells must acquire the ability to continuously proliferate in order to transform into 
malignant phenotypes. However, cells have internal programs (anti-growth signaling) to 
oppose limitless growth. In order to continue to proliferate, cancer cells must somehow 
evade many anti-growth signals. In general, anti-growth signaling is mediated by the 
activation of tumor suppressor genes. The Cancer Genome Atlas has compiled data 
encompassing all tumor types, which indicates that p53 is the most frequently mutated 
tumor suppressor gene followed by PTEN, APC, ATM, BRCA2, VHL, RB, CDKN2A, 
BRCA1 and WT1.
Retinoblastoma protein 1 (RB1) was the first identified tumor suppressor and deletion of this 
gene is frequently found in cancers [93]. In many cases, the loss of RB is due to defects in 
upstream signaling molecules such as inactivation of INK4. Loss of p16ink4a results in 
unopposed activation of CDK4/6, which phosphorylates the RB protein thereby activating 
E2F-mediated transcription of genes involved in entry into the cell cycle [94].
Another tumor suppressor frequently deleted due to chromosomal loss is p53 [95]. In fact, 
more than 50% of all tumors have loss of p53 tumor suppressive functions. Recently, mutant 
p53 has gained renewed attention due to the fact that along with the loss of tumor 
suppressive functions, mutant p53 gains oncogenic/tumor promoting functions [96].
Epigenetic silencing of tumor suppressor proteins, which includes DNA methylation, histone 
methylation and acetylation, is another mechanism through which tumor cells evade anti-
growth signaling. Many tumor suppressor genes have been found to have promoter 
hypermethylation in cancers [97]. Finally, anti-growth signaling plays a major role in 
treatment response and drug development. For example, the patients with human papilloma 
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virus-positive oropharyngeal cancer mostly retain wild-type p53 and have better prognosis 
and survival.
Although genetic alterations are mostly irreversible, epigenetic repressions are potentially 
reversible and targets for drug development. At least three histone deacetylase inhibitors, 
belinostat, vorinostat and romidepsin, are currently approved by the US FDA for cancer 
treatment. Many natural compounds also target the restoration of tumor suppressors through 
modifying epigenetic changes [98–102]. Thus, approaches to activate anti-growth signaling 
will open another chapter for cancer prevention and therapy.
The prioritized targets for anti-growth signaling are RB, p53, phosphatase and tensin 
homolog (PTEN), Hippo, growth differentiation factor 15 (GDF15), AT-rich interactive 
domain 1A (ARID1A), Notch, IGF-1R and others. The approaches are inactivation of E2F 
by down regulation of pRb using CDK inhibitors, activation of p53 through up-regulation of 
wild-type p53, activation of PTEN to inhibit PI3K-AKT, activation of Hippo pathways by 
inhibiting Yes-associated protein/transcriptional enhancer activator domain (YAP/TEAD) 
activity, induction of GDF15 through p53 activation, activation of ARID1A, blocking Notch 
pathway, and inhibition of IGF-1R to restore tumor suppressor pathways. Suggested 
phytochemicals for these approaches are EGCG, luteolin, curcumin, genistein, resveratrol, 
withaferin A, and deguelin. Furthermore, while the evasion of anti-growth signaling is a 
critical hallmark of cancer, other hallmarks are similarly important and a more integrative 
approach is necessary to simultaneously target several hallmarks of cancer to combat this 
deadly disease.
3.4 Resistance to apoptosis
Apoptosis naturally removes aged and unhealthy cells from the body [103]. However, in 
cancer, cells lose their ability to undergo apoptosis leading to uncontrolled proliferation and 
multiplication. These malignant cells are often found to overexpress many of the proteins 
that play important roles in resisting the activation of the apoptotic cascade, and one of the 
major hallmarks of human cancers is the intrinsic or acquired resistance to apoptosis [104]. 
Evasion of apoptosis may contribute to tumor development, progression, and also to 
treatment resistance, since most of the currently available anticancer therapies including 
chemotherapy, radio- and immunotherapy primarily act by activating death/apoptotic 
pathways in cancer cells [105]. Hence, a better understanding of the molecular mechanisms 
underlying tumor resistance to apoptotic cell death is expected to provide the basis for a 
rational approach to develop molecular targeted therapies.
Apoptosis resistance is multi-factorial and emanates from the interactions of various 
molecules and signaling pathways at multiple levels. Several mechanisms exist allowing 
cells to escape programmed cell death. Among them is the overexpression of the anti-
apoptotic molecules. B-cell lymphoma-2 (Bcl-2) family proteins play a critical role in the 
biology of apoptosis resistance. Robust agents against the Bcl-2 homology domain 3 
proteins are in development and accelerating toward clinical application. Other cell death 
mechanisms such as autophagy and necrosis can also be highlighted and strategies against 
them exist, including the use of natural agent such as EGCG. The role of the chaperone 
protein heat shock protein 70 (Hsp70) in apoptosis resistance is important, and natural 
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agents may also address this. Various molecular mechanisms support resistance to apoptosis 
in different disease models such as glioblastoma, multiple myeloma and chronic 
lymphocytic leukemia. Epigenetic players, particularly the non-coding RNAs/ microRNAs, 
are also of importance. Novel targets can be pinpointed, such as ecto-nicotinamide 
dinucleotide disulfide thiol exchanger protein (ENOX) and nuclear export protein 
chromosomal regional maintenance protein 1(CRM1), along with specific strategies to 
overcome these important drug resistance promoters. Other targets include inhibition of 
Mcl-1, activation of tumor autophagy, activation of tumor necrosis, inhibition of Hsp90, 
inhibition of proteasomes, and inhibition of EGFR and Akt. Approaches to these targets 
include gossypol, UMI-77, EGCG, triptolide, PXD, selinexor, and inhibitors of EGFR and 
Akt. Collectively, the knowledge gained through greater understanding of the apoptosis 
resistance targets and specific strategies is anticipated to bring forward a broad form of 
therapy that could result in better treatment outcome in patients suffering from therapy-
resistant cancers.
3.5 Replicative immortality
Replicative immortality, the ability to undergo continuous self-renewal, is necessary for 
propagation of normal germ cells, but is not a property of normal somatic cells. When 
acquired by somatic cells that have sustained genetic damage or instability, replicative 
immortality allows accumulation of sequential aberrations that confer autonomous growth, 
invasiveness, and therapeutic resistance [106]. As a result, several mechanisms have evolved 
to regulate replicative potential as a hedge against malignant progression [107]. Senescence, 
a viable growth arrest characterized by the inability of affected cells to resume proliferation 
in the presence of appropriate mitogenic factors, is a specific response to the gradual 
shortening of chromosomal end structures (telomeres) with each round of cell replication, 
and a more general response to oncogenic and genotoxic stresses. Senescence often involves 
convergent interdependent activation of tumor suppressors p53 and p16/pRB [108,109], but 
can still be induced, albeit with reduced sensitivity, when these suppressors are inactivated. 
Doses of conventional genotoxic drugs required to achieve cancer cell senescence are often 
much lower than doses required to achieve outright cell death [110]. Additional targeted 
therapies may induce senescence specifically in cancer cells by blocking cyclin-dependent 
kinase mediated inhibition of RB-family proteins [111], or by exploiting cancer cells’  
heightened requirements for maintenance of telomere length through the action of the 
enzyme telomerase [112]. Developing optimized and truly holistic cancer prevention and 
treatment regimens will likely incorporate strategies that target replicative immortality.
The chief advantage to be gained by the use of senescence-inducing therapeutic regimens is 
elimination of the tumor’ s repopulating ability with reduced collateral damage compared to 
conventional cytotoxic regimens. There are, however, certain questions and risks associated 
with this strategy that must be addressed before its clinical adoption. In the case of telomere 
and telomerase based strategies, replicative senescence may occur more readily in rapidly 
dividing cancer cells bearing short telomeres than in slowly dividing stem cells with 
comparatively longer telomeres, but telomere lengths in cancer cells may still be long 
enough to permit sufficient population doublings for invasion and metastases to occur [112] 
Moreover, telomere dysfunction promotes the development of chromosomal instability, 
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which in turn can generate mutations that enable cells to become drug resistant and/or 
activate mechanisms based on alternative lengthening of telomeres for telomere maintenance 
and/or become more malignant [113]. High priority should therefore be given to further 
research into the determinants of senescence stability, as the implications of delayed cell 
cycle re-entry, permanent cytostasis, or eventual clearance may be profoundly different. 
Lower doses of genotoxic drugs needed to induce senescence may reduce collateral damage 
to critical normal cells, but allow establishment of dormancy and/or adaptive resistance by 
cancer cells. The microenvironmental and systemic effects of senescent cells also need 
further clarification, as factors secreted by senescent cells may promote tumorigenic changes 
in nearby cells. Conversely, since it is almost impossible to kill all the cells in malignant 
tumors even using the highest tolerated doses of chemotherapy, combined use of an agent 
that induces or enhances stable senescence in the cancer cells that manage to retain viability 
might additively or synergistically increase therapeutic efficacy.
A number of potential targets can be singled out for further research, including telomerase, 
human telomerase reverse transcriptase (hTERT), mammalian target of rapamycin (mTOR), 
CDK4/6, CDK 1/2/5/9, Akt and PI3K. Several approaches deserve further research, although 
the activity of the phytochemicals in particular is still far from clinical utility. These include 
imetelstat, genistein, perillyl alcohol, palbociclib, dinaciclib, curcumin and EGCG.
3.6 Dysregulated metabolism
Dysregulated metabolism is a hallmark of cancer in which many cancer cells show increased 
glucose uptake and produce lactate. This characteristic is often called the “Warburg effect” 
[114], but how and why cancer cells reprogram their metabolic state is not well understood. 
Recent research has focused on understanding the metabolic changes accompanying 
oncogenesis [27]. A new model of cancer metabolism positions metabolic rewiring in cancer 
as a coordinated process to support rapid cellular proliferation by tuning cellular energy 
production needs towards biosynthetic processes. Indeed, several metabolic shifts associated 
with cancer can be linked to cellular growth, which serve to support biosynthesis of lipids, 
proteins, nucleic acids required for tumor formation and survival [115].
In several cases, expression of oncogenes and/or loss of tumor suppressors lead directly to 
changes in metabolism, by expression, activity, or flux of key metabolic nodes. Several 
components of glucose and glutamine metabolism have emerged as important regulators of 
metabolism in cancer. In glucose metabolism, hexokinase 2 (HK2), 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and pyruvate kinase isoform M2 (PKM2) all 
regulate glycolytic flux. Using a “kitchen sink” analogy for glycolysis, both HK2 and 
PFKFB3 are regulators of the faucet, and fill up the sink. Conversely, PKM2 regulates the 
drain. Cancer metabolism turns on the faucet and plugs the drain, which over-spills the 
glycolytic pathway and provides metabolites used as building blocks for cellular growth. 
Efforts are underway to identify therapeutic strategies to “turn off the faucet” or “unplug the 
drain” in glycolysis, limiting cellular growth in cancer. Recent studies have also determined 
that glutamine is used as a fuel (glutaminolysis) in proliferating cancer cells. Glutamine 
oxidation can provide carbon and nitrogen for growth, and therefore is an attractive 
therapeutic target in cancer. Additionally, mutations in genes encoding enzymes directly 
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involved in metabolic pathways have been associated with several types of cancer. Rather 
than acting as a bystander or facilitator of oncogenesis, aberrant metabolism now has a pro-
oncogenic role and has led to the redefinition of some metabolites as ‘ oncometabolites’  
[116]. Indeed, these oncometabolites are powerful influencers of proliferation, and are also 
positioned as new therapeutic targets.
In principle, a broad-spectrum approach to target metabolic shifts in cancer is likely to be a 
promising therapeutic strategy. However, studies using this approach to target dysregulated 
metabolism in cancer are in their infancy. Lessons could be learned from other strategies to 
target mitochondria or to target metabolism in order to identify efficacious and safe therapies 
targeted at cancer metabolism; some drugs targeting metabolism are being re-purposed for 
their antitumorigenic effects. Several approaches could be mentioned, such as 3-
bromopyruvate, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3-
aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2’ ,3’ :
4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46), dichloroacetate, hexachlorophene, bis-2-(5-
phenylacet-amido-1,2,3-thiadiazol-2-yl)ethyl sulfide (BPTES) and 2,3-Dihydroxy-6-
Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic acid (FX11), but data for these 
must be regarded as extremely preliminary, and they lack sufficient justification to be 
included in therapy without further study. Most target proteins or pathways identified as 
having potential to manipulate cancer metabolism have not been directly tested in the 
context of other hallmarks. The emerging efficacy of physiological interventions that 
manipulate cancer outcomes, such as fasting, calorie restriction, or exercise, could influence 
cancer metabolism and other hallmarks of cancer [117]. Future studies directly testing the 
ability to manipulate dysregulated metabolism in cancer will be an important and exciting 
new area of cancer biology that has potential for treating a variety of cancers.
3.7 Tumor-promoting inflammation
Virchow first proposed the role of inflammation in cancer in 1863, while observing the 
presence of leukocytes in neoplasms, and empirical evidence has since underscored the 
importance of this linkage [118,119]. The inflammatory milieu promotes a cellular 
microenvironment that favors the expansion of genomic aberrations and the initiation of 
carcinogenesis [120]. Chronic inflammation is linked to various phases of tumorigenesis, 
such as cellular proliferation, transformation, apoptosis evasion, survival, invasion, 
angiogenesis and metastasis [121–123]. Inflammation is also known to contribute to 
carcinogenesis through the generation of reactive oxygen species (ROS) and reactive 
nitrogen species which can damage DNA at the site of the tumor [124]. Free radicals and 
aldehydes, produced during chronic inflammation, can also induce deleterious gene 
mutation and post-translational modifications of key cancer-related proteins [125].
In addition, chronic inflammation has an influence on immune system constituents that are 
directly linked with cancer progression. Under normal conditions, immune cells, including 
macrophages, granulocytes, mast cells, dendritic cells, innate lymphocytes, and natural killer 
(NK) cells serve as the front line of defense against pathogens. When tissue disruption 
occurs, macrophages and mast cells secrete matrix-remodeling proteins, cytokines and 
chemokines, which activate local stromal cells (e.g., fibroblasts, adipocytes, vascular cells) 
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to recruit circulating leukocytes into damaged tissue (acute inflammation), to eliminate 
pathogens [126]. However, when these processes are initiated in the tumor 
microenvironment, they are not resolved, which leads to chronic inflammation of the 
“damaged” (tumor) tissue. Thus, while acute inflammation normally supports and balances 
two opposing needs for the repair of damaged tissues (apoptosis and wound healing), 
chronic inflammation represents a loss of this balance and the resulting confluence of factors 
has deleterious implications for the immune system [127].
Accordingly, the relationship between tumor-promoting inflammation and cancer is 
important to consider. Macrophage migration inhibitory factor, cyclooxygenase-2 (COX-2), 
NF-ŢB, tumor necrosis factor alpha (TNF-ř), inducible nitric oxide synthase (iNOS), Akt, 
and chemokines are important antiinflammatory targets that might be suitable for a multi-
pronged therapeutic approach to inflammation suppression. Additionally, curcumin, 
resveratrol, EGCG, genistein, lycopene, and anthocyanins are forms of low-cost chemistry 
with little to no toxicity that could be employed to reach these targets.
Future translational work should make use of promising agents such as these (combined as 
constituents within a multi-pronged antiinflammatory approach) bearing in mind that some 
of these targets impact the immune system and can increase the risks associated with 
infection. Bioavailability challenges are also a concern for a number of these agents but 
recent advances in delivery systems will help address this issue.
3.8 Angiogenesis
Angiogenesis, the expansion of an existing vasculature, is the main mechanism of blood 
vessel growth in adults, and is therefore essential for tumor development [128]. Tumor 
angiogenesis is switched on by changing the balance between angiogenic factors and 
inhibitors in favor of angiogenesis [129], a process induced by tumor hypoxia as the tumor 
grows beyond a size of approximately 1 mm3 [128, 130]. At more advanced stages, 
progressive genomic instability in the tumor leads to mutations in pathways regulating the 
production of multiple angiogenic factors [131], and stroma cells also become important 
sources of sustained angiogenic factor production [132]. These collectively result in a 
stronger and more complex angiogenic factor profile. It is therefore not surprising that 
targeted neutralization of a single angiogenic factor, which has been the focus for 
antiangiogenic cancer therapy so far, rarely produces long-term, antitumor effects [132].
Due to the multifactorial nature of tumor angiogenesis this process is likely to be more 
efficiently treated by targeting multiple aspects of tumor angiogenesis and vascular 
dysfunction at the same time. Ten of the most important targets for tumor angiogenesis and 
vascular dysfunction are to inhibit endothelial cell migration/tip cell formation, reduce 
structural abnormalities of tumor vessels, reduce hypoxia, inhibit lymphangiogenesis, reduce 
elevated interstitial fluid pressure, reverse poor perfusion, normalize disrupted circadian 
rhythms, suppress tumor-promoting inflammation, deactivate tumor-promoting fibroblasts 
and normalize tumor cell metabolism/acidosis.
Currently available non-specific antiangiogenic agents, able to perform some of these tasks, 
are however quite toxic, which renders them unsuitable for long-term use [131,133,134]. 
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There is an urgent need to identify alternative compounds that could be used in combination 
over extended periods of time, targeting tumor angiogenesis broadly and thus lowering the 
risk of resistance. Plant-derived compounds, phytochemicals, are in many cases better 
tolerated than the synthetic analogues used in cancer therapy today. Furthermore, they often 
exhibit broader mechanisms of action and sometimes even higher affinity against important 
cancer targets compared to the synthetic alternatives [135]. Ten phytochemicals that may be 
effective as approaches to neutralize the 10 identified targets are oleanoic acid, tripterine, 
silibinin, curcumin, EGCG, kaempferol, melatonin, enterolactone, withaferin A and 
resveratrol. Further study is needed to determine the optimal use and combination of these 
phytochemicals in antiangiogenic therapy, focusing on delivery, toxicity and their use in 
prophylactic regimens.
3.9 Tissue invasion and metastasis
Cancer causes substantial patient morbidity and mortality globally, making it a key health 
issue. Metastatic dissemination of the disease to distant sites impacts prognosis, with 
metastatic diseases accounting for a vast percentage of cancer patient mortality 
[27,136,137]. Cancer cells must overcome particular obstacles in order to successfully 
disseminate to and establish at a secondary location, progressing through the metastatic 
cascade. Successful progression through this cascade is linked with numerous established 
changes in cellular functions leading to the acquisition of an invasive phenotype. This 
involves loss of cell-cell contact with the main tumor body, invasion, degradation and 
migration through surrounding tissue and extracellular matrix, secretion of angiogenic/ 
lymphangiogenic factors and intravasation to the blood/lymph vessel, transport around the 
body and evasion of the immune system, extravasation at the secondary site and 
establishment of a secondary tumor [138,139].
Hence, factors influencing these processes such as cell adhesion molecules, proteolytic 
matrix degrading enzymes, cell motility and factors involved in the process of EMT have all 
been subject to scientific scrutiny. Additionally, the complex heterogeneity within tumors, 
together with cellular interactions between tumor cells and other, non-cancerous, cell types 
have been established to play key roles in metastatic dissemination and add further 
complexity to this cascade [137, 138]. While advances in the field of cancer research have 
been made, the process of cancer metastasis and the factors governing cancer spread and 
establishment at secondary locations are still poorly understood. Current treatment regimes 
for metastatic disease pose many adverse effects, which can further negatively impact on a 
subset of patients generally presenting with poorer health conditions. Hence there is a great 
need to develop new therapeutics that not only target tumor growth and inhibit metastasis 
but that also have a lower toxicity and reduced inherent side effects. Factors associated with 
metastasis such disruption of E-cadherin and tight junctions, key signaling pathways, 
including urokinase-type plasminogen activator, PI3K/AKT, focal adhesion kinase, Ś-
catenin/zinc finger E-box-binding homeobox 1 and transforming growth factor (TGF)-Ś, 
together with inactivation of activator protein 1 (AP-1) and suppression of matrix 
metalloproteinase-9 (MMP-9) activity should be considered as key research priorities.
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The need can also be highlighted for new, low toxicity compounds, which interfere with 
these processes but remain inexpensive alternatives that are readily available and free from 
intellectual property. Phytochemicals, or natural products, such as those from Agaricus 
blazei, Albatrellus confluens, Cordyceps militaris, Ganoderma lucidum, Poria cocos and 
Silybum marianum, together with diet-derived fatty acids gamma-linolenic acid and 
eicosapentaenoic acid and inhibitory compounds have potential to inhibit these key 
metastatic events. These potential targets and strategies thus present new therapeutic 
opportunities to both manage cancer metastasis as well as having holistic effects against 
many of the hallmarks of cancer.
3.10 Tissue interactions in the tumor microenvironment
Cancer arises in an in vivo tumor microenvironment. This microenvironment is a cause and 
consequence of tumorigenesis, and consists of cancer cells and host cells that co-evolve 
dynamically through indirect and direct cellular interactions, producing metabolites and 
secreting factors that affect cancer progression [140,141]. In turn, this environment regulates 
the ability of a cancer to grow and survive via multiscale effects on many biological 
programs including cellular proliferation, growth and metabolism, as well as angiogenesis 
and hypoxia, innate and adaptive immunity [142]. Specific biological programs could be, 
based on our most recent understanding, exploited as targets for the prevention and therapy 
of cancer, including: the inhibition of cholesterol synthesis and metabolites, ROS and 
hypoxia, macrophage activation and conversion, regulation of dendritic cells, regulation of 
angiogenesis, fibrosis inhibition, endoglin, and cytokine signaling. These programs emerge 
as examples of important potential nexuses in the regulation of tumorigenesis and the tumor 
microenvironment that can be targeted.
Potential targets include metabolic programs that may broadly influence many cell biology 
programs that impact tumorigenesis and the tumor microenvironment (cholesterol synthesis 
and metabolites, ROS and hypoxia), inflammation, innate and adaptive immunity-related 
programs (macrophage conversion, dendritic cell activation, immune signaling), host 
microenvironment associated cellular programs (fibrosis, angiogenesis), and cytokine-
mediated regulatory programs (IL-6, endoglin, and JAK). We have particularly focused on 
identifying approaches for inhibiting these targets that included natural products that have 
been suggested to have significant anticancer activity. Some of these molecules may more 
generally influence tumorigenesis and the microenvironment (berberine), others more 
specifically target ROS (resveratrol, desoxyrhapontigenin), macrophage conversion (onionin 
A), indoleamine 2,3-dioxygenase (IDO) regulation of dendritic cells (EGCG), cholesterol 
synthesis (genistein), fibrosis (naringenin), inflammation and immune signaling (piperine) 
and JAK signaling (zerumbone). This approach will provide a starting point for examining 
synergies that might be anticipated in testing certain targets and/or mixtures of natural 
chemical constituents that may modulate the tumor microenvironment in the treatment and 
prevention of cancer.
3.11 Immune system evasion
Tumors evade immune attack by several mechanisms including generation of regulatory 
cells and their secretions, defective antigen presentation, induction of immune suppressive 
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mediators either by cancerous cells themselves or by those in the microenvironment, 
tolerance, immune deviation and apoptosis.
Current approaches to immune therapy include a) cellular targets, b) molecular targets, c) 
vaccination therapy, d) therapy by phytochemicals, e) adoptive T cell therapy and f) 
immunomodulatory antibodies. Of these anticancer agents, the most important are those that 
are targeted in nature and to lesser extent, those that are non-specific in nature. Targeting 
specific costimulatory molecules such as cytotoxic T-lymphocyte-associated protein-4 
(CTLA-4) [143] or programmed cell death protein (PD1/PD-L1) [144] is considered an 
important anticancer strategy. Also, anti-PD-1 antibodies are showing enormous therapeutic 
potential in advanced cancers. Targets that are considered appropriate for broad-spectrum, 
low-toxicity therapeutics are less specific and include enhancing Th1 responses, enhancing 
śŜ T cells, activation of macrophages, inhibition of Treg lymphocytes, enhancing natural 
killer cell activity and induction of IL-12.
There are a number of important nonspecific anticancer agents that have been reported, 
including vaccination therapy, as well as nonspecific bacteria-based therapies [145], and 
phytochemicals [146–148]. Phytochemicals (the biologically active components of fruits and 
vegetables) have been shown to exert protective effects against cancer. Examples of potential 
phytochemical approaches include extracts of Ganoderma lucidum, Trametes versicolor, 
Astragalus membranaceus, and Lentinus edodes, as well as astaxanthin and the polyphenol 
resveratrol analogue HS-1793. There is, however, a downside to phytochemical therapy such 
as their poor absorption by humans and rapid metabolism and excretion. More work is 
required to assess which phytochemicals block evasion of immune surveillance and also to 
determine which phytochemicals promote antitumor responses in cancer patients before 
these can be recognized for therapeutic value in the clinic.
4 Summary of findings on targets and approaches in hallmark reviews
As described above, a cross-validation process was employed to review the proposed actions 
on each target and all of the approaches for known effects on other hallmark areas and the 
tumor microenvironment. Anticarcinogenic synergies and confounding/procarcinogenic 
effects were then compiled and summarized in Tables 1–3. Supplemental table S1, a sample 
cross-validation table for dysregulated metabolism approaches, was used in construction of 
Tables 2 and 3. Supplemental tables S2 and S3 contain the aggregated cross-validation tables 
from each review (with references omitted). More detailed discussion of these interactions 
can be found in the individual hallmark reviews.
Table 1 shows an alphabetical listing of prioritized targets from each hallmark review, as 
well as the number of contrary, controversial, none known and complementary interactions 
with all other hallmarks. Dysregulated metabolism targets do not appear in the table; too 
little is known about the targets in this new area of research to reliably assess their 
interactions with other hallmarks. Of these relationships, 3.98% were contrary, 7.62% were 
controversial, 21.74% of interaction assessments found no known relationship, and 66.71% 
were complementary.
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Table 2 shows the prioritized therapeutic approaches – the phytochemicals, plant extracts 
and drugs chosen as modifiers of the priority targets. Of these, 1.08% were contrary, 7.62% 
were controversial, 34.05% had no known relationships and 62.1% were complementary. 
Both contrary and controversial interactions indicate potential conflict among the targets and 
approaches selected for different hallmarks that could result in a broad-spectrum approach 
with antagonistic, rather than synergistic effects.
The small number of contrary and controversial interactions is encouraging, and suggests 
that the potential for negative interactions among the selected targets and approach may be 
limited. However, this may also reflect the common bias in the literature to publish positive 
antitumor effects. Nearly a third of potential interactions were listed as having no known 
relationship, suggesting the need for substantially more research in this area. The large 
number of complementary interactions is also encouraging but may result from indirect or 
bystander effects.
Table 3, in which the different types of interactions of both targets and approaches are listed 
for each hallmark, reflects different levels of knowledge regarding hallmarks, as well as 
varying prevalence of complementary approaches. Genomic instability has the largest 
number of unknown relationships with the targets and approaches. On the other hand, tumor 
microenvironment, tissue invasion and metastasis and resistance to apoptosis have the 
highest number of complementary interactions for both targets and approaches. Small 
numbers of contrary interactions were found for the different hallmarks for both hallmarks 
and approaches, but the number of targets for replicative immortality and angiogenesis, 
reflecting mixed positive and negative interactions, were larger than for other hallmarks.
There are a number of limitations that should be noted in this delineation of cross-hallmark 
relationships. First, the researchers who assembled these results were not asked to 
distinguish between direct effects on other hallmark areas and reported effects on other 
hallmark areas that may have resulted in an indirect or “bystander” effect mediated through 
a different mechanism. In many cases, but not all, this distinction was made. Therefore it is 
likely that some of the complementary interactions do not represent a fully independent 
cross-hallmark relationship, but rather are simply indicative of some sort of downstream 
effect (e.g., within a signaling cascade or via some other signaling molecule that exerts 
pleiotropic effects). However, we did not feel that this project needed to investigate the 
nature of these complementary interactions in detail, especially since the clinical impacts of 
these interactions would be similar for indirect and direct effects. Instead, our main concern 
was focused on the possibility that a large number of cross-hallmark relationships might be 
revealed where actions with procarcinogenic or tumor-promoting potential had been 
reported. It was more important to identify contrary and controversial cross-hallmark 
interactions than complementary ones, since targets or approaches that exert procarcinogenic 
actions would normally need to be more carefully assessed (or avoided altogether) in the 
development of combination approaches or interventions.
The second limitation of these reports of cross-hallmark relationships is related to data 
quality. In some instances, the available evidence used to support the indication of a cross-
hallmark relationships was robust, consisting of multiple studies involving detailed in vitro 
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and in vivo findings. In other instances, however, the underlying evidence that was used to 
report the existence of a cross-hallmark relationship was quite weak (e.g., consisting of only 
a single in vitro study involving a single cell-type). Again, the overarching goal in this 
project was to create a foundation that would allow us to look systematically across the 
literature in each of these areas, to help us shape the selection of the targets and approaches 
in order to comprehensively counter tumor growth pathways. So although we realized that 
not all of these reports of cross-hallmark relationships represented the same level of 
evidence, we still wanted to examine available evidence to flag targets and approaches where 
procarcinogenic actions had been reported.
There was also considerable debate within the task force over the value of tables containing 
only a simplified indication of a relationship (i.e., + or −) supported by evidence that varied 
considerably in quality. But since many individual studies and reviews that focus on 
therapeutic approaches fail to work systematically across the spectrum of incidental actions 
that might result from combining therapies, it was our opinion that a tabularized framework 
was the only way to ensure that we had assembled a complete view of cross-hallmark 
activity.
The types of approaches selected differed among different review teams. While some review 
teams selected all or mostly phytochemicals or plant extracts, some teams felt that the 
evidence for these was insufficient, and emphasized other types of molecules, including 
drugs in development. These may pose more difficulties for translational investigators due to 
intellectual property, toxicity or other concerns, but may offer advantages in a more clear 
understanding of their mechanisms. We suggest, however, that the approaches as well as the 
targets presented in Tables 1 and 2 can be viewed as simply a model for broad-spectrum 
cancer therapies, rather than as a final list. Some of the recommended approaches are clearly 
experimental, and further research will likely discover compounds, phytochemical or 
synthetic, that are not on this list that may be useful in a broad-spectrum approach. The 
prevalence of interactions where no interactions were found – over 20% for targets and over 
30% for approaches – also suggests caution and a need for further research investigating 
potential cross-hallmark relationships as well as other mechanisms that may lead to 
toxicities.
Bioavailability of the phytochemicals chosen will also be a concern for future studies. The 
need for development of better preclinical models for screening compounds and testing 
rationally designed combinatorial therapies composed of compounds from any source is also 
obvious, and should clearly be a first step in the development of the broad-spectrum 
approach.
4.3 Role of integrative therapies in the broad-spectrum approach
Integrative medicine is an approach to health and healing that “makes use of all appropriate 
therapeutic approaches, healthcare professionals and disciplines to achieve optimal health 
and healing” [149]. A comprehensive integrative medicine intervention for cancer patients 
typically includes nutrition education, mind-body medicine and physical activity 
components, as well as dietary supplements including herbs, nutraceuticals and 
phytochemicals [3,150]. Such an intervention may contribute uniquely to a broad-spectrum 
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therapeutic approach through its impact on a wide variety of relevant molecular targets and 
hallmarks. Hallmarks that may be particularly impacted include genomic instability, tumor-
promoting inflammation, dysregulated metabolism and immune system evasion. Because of 
their susceptibility to manipulation by diet, exercise and supplementation, these may be 
characterized as metabolic hallmarks.
Nutrition has long been the primary focus of research on integrative interventions for cancer. 
The World Cancer Research Fund and the American Institute for Cancer Research find that 
diets high in fruits and vegetables substantially reduce risks of several cancers [151]. Cancer 
prevention diets are also suitable after a cancer diagnosis [152]. For example, colon cancer 
patients eating a Western diet after diagnosis were at higher risk for recurrence and mortality 
than those with healthy diets [153]. Breast cancer patients who followed low-fat diets were 
found to have lost weight and had lower recurrence risks, especially among patients with 
estrogen receptor-negative cancers [154]. Trials of diets enriched in whole grains, low-
glycemic diets, and both low-fat diets and Mediterranean diets enriched in olive oil and 
almonds reduced levels of inflammation as measured by CRP [155–158]. Low fat diets, 
weight loss and supplements (anthocyanins and fish oil) have been observed in randomized 
trials to reduce cytokines and signaling molecules [159–162]. Mind-body interventions have 
emphasized immune targets, with findings of interventional trials including activation of T 
cells and lymphokine-activated killer cells and increased natural killer cell activity 
[163,164]. Exercise interventions have documented effects on survival, IGF-1, natural killer 
cell activity, and sex hormones [165–168]. While much work remains to be done on 
integrative interventions, preliminary data suggest that integrative medicine may 
significantly support a broad-spectrum approach to cancer therapy.
5 Proposed research model
The review process for this project has revealed many potential targets and approaches. The 
cross-validation activity suggests that only a small number of targets and approaches affect 
other hallmarks in contrary or controversial ways. Indeed the results suggest that the design 
of a broad-spectrum approach should in fact be feasible from a safety standpoint. Although 
considerable research will be needed, disease relapse is a substantial and longstanding 
problem, so this novel model definitely warrants further investigation.
5.3 In vitro research
An array of in vitro models is available for preliminary study of broad-spectrum formulas. 
One question is the suitability of receptor-based assays versus cell-based assays. While 
receptor-based assays may seem more suitable for targeted therapy research, examining the 
impacts of a putative agent on a molecule such as NF-ŢB, which is at the intersection of 
multiple signaling pathways related to inflammation, might be advised. Cultivated cell lines 
are valuable for preliminary screening of mixtures, but are, in most respects, limited in their 
predictive ability. Isolated cell lines from clinical samples are an alternative, and use of 
transformed cancer cells versus non-transformed lines should be discussed. Tissue and organ 
explants are another useful in vitro model.
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Basic research on the properties of the natural product and other approaches selected in the 
reviews needs to continue. The pharmacology of mixtures and combinations of 
phytochemicals, bioavailability, dose optimization and synergy are among the areas in which 
research is needed for many phytochemicals [169,170]. However, multicomponent herbal 
therapies used in traditional and alternative medicine have not received detailed analysis. 
Network pharmacology could be a means of exploring these presumed synergisms, and 
efforts are being made to apply this approach to the complex herbal mixtures used in 
traditional Chinese medicine [171]. Studies on the pharmacokinetics of herbal extracts and 
phytochemicals, which often begin at the in vitro level, are also needed [172].
In sum, given the complexity that is immediately suggested when combinations of 
approaches are possible, we strongly recommend that well-coordinated, multi-faceted 
programs be pursued initially to ensure that the constituent approaches that are selected are 
well-characterized using in vitro models, and that delivery methods that are selected for in 
vivo work receive careful evaluation before animal research is undertaken.
5.4 In vivo research
Multiple in vivo models for further study of broad-spectrum approaches are also available. 
Two obvious choices are animal tumor models and human tumor xenografts implanted in 
athymic mice. While human tumor xenografts have the advantage in predicting effects of 
agents on human cancer cells, animal tumors offer some interesting choices for 
chemoprevention studies, since several are induced by exposure to various chemicals. The 
rodent tumors are questionable, however, in their ability to predict human responses to 
antitumor therapy. Differences in immunity are one consideration, most obviously with 
athymic mice but also with other animals. Many other differences are known. Rodents and 
humans, for instance, differ significantly in their blood levels of soy isoflavones after these 
are administered through a variety of dietary and experimental routes [173]. Isoflavone 
levels in rodent blood 20 to 150 times those in humans after similar oral intake have been 
observed, raising questions about the suitability of animals for prediction of phytochemical 
effects in humans.
Additionally, as shown in different preclinical mouse models, immune and inflammatory 
responses to cancer differ in young and old individuals, and many cancer treatments are 
likely to be less effective at older ages. Combination treatment including immunotherapeutic 
approaches may be most suitable for older animals. Therefore, there is a strong argument for 
testing and optimizing combination treatments in suitable model systems before attempting 
to apply them to cancer patients. The US National Cancer Institute Mouse Models of Human 
Cancer Consortium [174] has tried to provide the scientific community with accurate, 
reproducible models of human cancers that can be used in translational and preclinical 
studies. Such improved models could be of great importance for developing combination 
treatment strategies. Companion animals, such as dogs and cats, which experience several 
tumors analogous to human cancers, can also act as comparative models for human tumors. 
[175].
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5.5 Clinical trials
Keeping in mind that a broad-spectrum approach may be used not only by itself, but also as 
adjuvant therapy with conventional agents, there are numerous potential settings for clinical 
trials, either for proof of principle or therapeutic goals. Preliminary studies could include 
metabolomic studies to identify metabolites of dietary interventions, or the pharmacokinetics 
and pharmacodynamics of phytochemical agents. A variety of settings can be contemplated 
for clinical trials. One period during which a broad-spectrum approach may be particularly 
appropriate is the perioperative period. Murine data demonstrate that tumor growth 
accelerates after surgery; there are also numerous anecdotal reports regarding cancer patients 
in whom rapid growth of metastatic tumors has been noted after surgery [176–181]. Further, 
there is reasonable human evidence that colon or rectal resection results in significant 
increases in the plasma levels of numerous proangiogenic proteins after surgery [182–185]. 
This period is not generally used for chemotherapy administration because of fears of 
impaired wound healing, but the above findings provide the rationale and motivation for 
systemically administering selected anticancer agents perioperatively.
Several non-standard chemotherapy agents, including phytochemicals, have been 
administered perioperatively in small studies. [186–188]. These agents upregulate immune 
function via nonspecific mechanisms. A Phase I trial assessing the combination of EGCG 
and silibinin in colorectal cancer is underway, with both agents given orally before and after 
surgery. [189–191]. Such trials represent an innovative approach to clinical assessment of 
natural products that can be carried out within a restricted time.
Although clinical trials of phytochemicals and plant extracts in cancer are limited compared 
to those with conventional chemotherapy, they are by no means lacking. Russo et al. [58] 
review nearly 50 ongoing and completed trials of phytochemicals and extracts in cancer 
prevention and therapy, noting that even though clinical research is still limited, preliminary 
results are promising. Most of the 50 studies took place in the United States, and most 
included a single phytochemical or single-herb extract. Nearly 3000 controlled trials of 
Chinese traditional medicine, 90% concerning herbals, were reviewed by Li et al. [192]. 
Only 16% of traditional medicine trials in this review reported use of adequate methods of 
randomization, and only a very small percentage reported study blinding, although quality of 
studies improved through time. Most Chinese herbal formulas contain multiple herbs and are 
aimed at many targets.
The design and execution of clinical trials of natural chemicals from plants and foods, 
however, has been challenging worldwide. An herbal products extension of the Consolidated 
Standards of Reporting Trials (CONSORT) randomized trial reporting guideline has been 
published to help improve herbal trial reporting [193]. A review of published studies of 
Panax ginseng, which is common in Chinese formulas but has been studied globally for 
many conditions, found that only 48% of them reported CONSORT-suggested items, and 
only 39% reported items from the herbal products extension [194], although these study 
designs also improved over time.
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5.6 Translational considerations
Assuming that translational research work will involve a substantial combination of 
therapeutic agents such as those proposed in Table 2 as a starting point, a first step would be 
the selection of specific targets and approaches for preliminary study. To achieve a truly 
broad-spectrum effect, one strategy might be to use small doses of every approach that lacks 
significant contrary interferences. While such a mixture might be made up and applied to 
cell lines, it could be questioned whether the concentrations that could be achieved in the 
cells would be physiologically relevant, especially given the low bioavailability of many 
phytochemicals. Most in vitro work on single phytochemicals, however, has actually been 
conducted at high concentrations that are not achievable in humans. The pharmacokinetics 
and pharmacodynamics of phytochemicals are complex and many are not yet well known, 
although progress is being made on some agents [195]. Another method to narrow the 
number of phytochemicals that need to be in an agent might be to select the phytochemicals 
that are most widely represented across hallmarks, such as curcumin and resveratrol, and 
analyze combinations of these agents. Some of the selected approaches, e.g. silibinin, appear 
to have favorable pharmacokinetics [196]. Other phytochemicals with favorable 
pharmacokinetics could also be considered for inclusion in a broad-spectrum agent, such as 
phenethyl isothiocyanate [197]. Research is also urgently needed on the question of the 
stability of phytochemicals as well as synthetic compounds in mixtures.
Alternative approaches to the question of bioavailability are being explored, especially with 
the polyphenols. One of the main issues with these compounds, which include quercetin, 
green tea catechins, curcumin and others, is ensuring that circulating doses of aglycones 
(one of the active forms of these molecules), are sufficient for activity. After oral 
supplementation of foodgrade molecules at doses safe for humans (200–500 mg/day), only 
conjugated forms are found in the bloodstream. As an example, quercetin is not found in the 
plasma as aglycone or as the parent glycosides: at the doses usually employed in 
intervention studies, it would be found exclusively as methyl, sulfate or glucuronic acid 
conjugates [198]. This observation discloses a paradox common to many biologically active 
phytochemicals: if free aglycones are absent in vivo after a dietary intake or supplementation 
with high doses, how can we explain the high biological activity of these molecules, largely 
described in vitro?
Two main hypotheses can be considered. First, conjugated forms of some flavonoids (e.g. 
quercetin) may be biologically active. Second, after cellular uptake, these metabolites may 
be de-conjugated, regenerating the free aglycones. To sustain these hypotheses, key issues 
need to be addressed, such as the efficacy of mechanisms of uptake of polyphenol 
metabolites and the substrate specificity of each metabolite, which is largely unknown. The 
use of pure compounds tested in vitro may shed light on these questions. Alternatively, 
pharmacological doses (2–4 g/day) administered orally [199] may saturate the metabolic 
pathways of conjugation [200]. Efforts are being made, however, to improve bioavailability 
of these agents, such as microspheres [201], liposomes [202] and nanoparticles [203]. An 
additional complication is that individuals may vary in their absorption, distribution, 
metabolism and elimination of phytochemicals, based in some instances on genetic 
variability [204], dietary habits [205] and potentially on intestinal microbiota [206].
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Considerations of quality control are essential along the spectrum of research from in vitro 
studies to clinical trials. Good agricultural practice, correct botanical identification and good 
manufacturing practice are mandatory to prevent adulteration, contamination and toxicity 
[207]. The example of PC-SPES, a botanical cancer remedy that was found to contain 
indomethacin, warfarin and synthetic estrogens, leading to its withdrawal from the market in 
2002 resulted in greater awareness of the need for a strict approach to quality control [208].
6 Implementation of broad-spectrum research agenda
A variety of practical considerations come into play in translating the proposed research 
model into a developmental program. These include regulatory considerations, intellectual 
property, clinical considerations and funding.
6.3 Regulatory considerations
Research on the broad-spectrum model must be undertaken with regulatory constraints in 
mind. Laws controlling herbal medicines, which would likely apply to the broad-spectrum 
approach, typically have regulatory paths for herbal or traditional medicine products that 
differ from those for prescription drugs. Regulations relevant to traditional Chinese herbal 
medicines, perhaps the closest model for the proposed broad-spectrum approach, are 
reviewed by Fan et al. [209]. A few examples of national regulations regarding herbal 
medicines, traditional medicines and natural product drugs follow.
The United States has perhaps the most challenging regulations for drug approval, and 
regulations for mixtures are particularly complex. Some multicomponent formulas, have 
nevertheless been tested in clinical trials in the US [210,211], but are still being sold only as 
dietary supplements, without labeling for use in malignancy. The designation of the 
Botanical Drugs category may offer opportunities to broad-spectrum agents. A recent court 
decision declaring natural products unpatentable under US law adds an interesting wrinkle 
to the regulatory framework [212]. In Canada, development as a high-risk Natural Health 
Product could be considered [213]. China has a variety of regulatory categories that could be 
used for multicomponent natural product therapeutics [214]. The relevance of Chinese 
regulations for multi-targeted drugs has been explored [215]. In the European Union, the 
Marketing Authorization scheme for conventional drugs would need to be used, rather than 
the Traditional Herbal Regulation Scheme [216], increasing the challenge for developmental 
research. In India it is likely that New Chemical Entity approval would be required [217], 
since use in cancer would likely be considered beyond traditional herbal medicine usage. 
Japan allows herbal medicines to be registered as prescription or over-the-counter drugs 
[209]; prescription licensing appears likely for an anticancer therapeutic. A variety of 
regulations exist in other countries, which are beyond the scope of this paper, and which 
would need to be explored individually. We expect that working under these strict 
regulations will be difficult, but we do not see it as impossible.
An additional regulatory consideration is the acceptability of the broad-spectrum approach 
to institutionally-based ethical review boards needed for clinical research. In institutions 
located in countries in which multi-component herbal formulas are typical of traditional 
medicine, ethical approval of such formulas is common, as suggested by the large numbers 
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of clinical studies on traditional Chinese herbal medicine [192] and Japanese Kampo 
medicine [218]. Trials with multi-component formulas and natural products have been 
conducted under other regulatory schemes as well. For instance, Phase I and Phase Ib studies 
of BZL101, an extract of Scutellaria barbata in metastatic breast cancer have been conducted 
in the United States [219,220]. A 4-herb combination originating in traditional Chinese 
medicine, PHY906, has been the subject of a Phase I trial as an adjunct to capecitabine in 
advanced pancreatic cancer, also in the United States [221]. In general, provision of 
sufficient preclinical and drug formulation information, review of prior clinical studies, and 
possession of appropriate approvals from national-level agencies will facilitate approval of 
study protocols.
6.4 Intellectual property
Herbs and natural products in their native forms do not have intellectual property protection, 
which should help in developing a low-cost, broad-spectrum formulation. Specified extracts 
and individual phytochemicals may have intellectual property of various types. Researchers 
could pursue intellectual property protection for specific broad-spectrum therapeutics they 
develop, as well as licensing to a pharmaceutical company with sufficient resources to 
support development and testing of the agent. Herbal extracts of some complexity have 
received patent or trademark status, and have been granted drug approval even in the United 
States, Examples include a mixture of green tea polyphenols known as Polyphenon E and 
sold as a patented drug sinecatechins for genital warts [222], and crofelemer, an extract from 
the South American plant Croton lechleri, approved for HIV-induced diarrhea [223]. The 
complexities of natural product patenting are beyond the scope of this paper but are covered 
in depth elsewhere [224].
6.5 Clinical considerations for a multi-component natural product therapeutic
Based on current clinical experience with natural products administered together with 
conventional drugs, one may anticipate potential concerns with broad-spectrum therapeutics 
that would be administered jointly with conventional therapies. A primary concern is the 
interactions between drugs and herbs or phytochemicals, including both pharmacokinetic 
and pharmacodynamic interactions [225]. This has been of special concern in oncology due 
to the life-threatening consequences of lowered blood levels of drugs, and the potential for 
severe side effects when blood levels of a drug are increased or actions of herbal products 
reinforce those of conventional agents. Antiplatelet activity is common in natural products 
[226], and may aggravate clinical consequences in patients with thrombocytopenia due to 
chemotherapy or other drugs [227]. Several other examples of negative interactions are 
known or suspected. St John’ s wort (used for depression), contains the strong cytochrome 
P450 3A4 inducer hyperforin, which is known to reduce blood levels of many drugs, 
including irinotecan [228]. Green tea, which is often taken in high doses by cancer patients, 
has potential interactions with sunitinib [229], with hepatotoxic drugs [230], and with 
bortezomib. On the other hand, positive interactions have been observed with green tea and 
erlotinib, a combination now in clinical trials [231]. Curcumin is one of several natural 
products that act as chemosensitizers and radiosensitizers for several tumors, while 
protecting normal tissues [232]. The ability of herbs and other natural products to relieve 
treatment-related side effects should not be overlooked [233,234].
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Furthermore, many natural products possess antioxidant activity. The role of oxidation in 
cancer progression and treatment is controversial [235]. Oxidative stress is increased in late-
stage disease [236], which suggests that suppression would be beneficial. Antioxidants may 
relieve some adverse treatment effects caused by the reactive oxygen species generated by 
many chemotherapy drugs, but data on this point are not conclusive [237,238]. Randomized 
trials of antioxidant supplements given with chemotherapy do not find evidence of reduced 
efficacy, but research with better study design and larger sample size should be conducted 
[239]. Additionally, some natural antioxidants, including the polyphenols, manifest pro-
oxidant properties in cancer cells, due to interactions with metal ions, which contribute to 
anticancer effects [240]. This pro-oxidant effect has been hypothesized to underlie the 
broadly multi-targeted actions of polyphenols such as curcumin and EGCG [241]. However, 
activity of most chemotherapy drugs depends on generation of ROS which should not be 
abrogated. Additionally, some oxidative metabolites may act as signaling molecules with 
anticancer activity [242]. Further, intracellular antioxidants may contribute to drug resistance 
[243]. Our understanding of the interactions of antioxidants and cancer thus continues to 
develop [244]. Patients are often warned not to supplement with antioxidants during 
treatment.
6.6 Funding
Development of new clinical agents that could be approved by regulatory agencies is an 
expensive endeavor. A recent economic model of drug discovery and development in the 
United States used industry-appropriate assumptions to estimate that the fully capitalized 
cost of a typical new single-molecule drug developed is now approximately $1.8 billion, 
63% of which is attributable to clinical development (Phase I–III studies) [245]. The details 
of such estimates are beyond the scope of this paper, but the financial challenges are clear. It 
is our contention that a multi-component broad-spectrum therapeutic approach is needed to 
complement and balance the current drug discovery paradigm, which focuses on narrowly 
scoped approaches and singular molecular targets, including targeted therapies, 
immunotherapy, “one mouse-one patient” avatars that identify personalized therapeutic 
regimens by implanting patients’  tumors into mice [246] and a variety of other approaches. 
Such an approach could be expensive to develop, and could face similar costs for trials and 
approval. However, a broad-spectrum approach could be aimed at wide applicability among 
many cancer types and subtypes. Thus, initial investment could be more easily recovered 
than is the case with narrowly-focused target therapies, since it would have utility across a 
large group of patients. Whether the development of the broad-spectrum approach should be 
carried forward by governments, for-profit pharmaceutical companies or even non-profit 
pharmaceutical companies is an open question.
6.7 Importance for low- and middle-income countries
The possibility that a broad-spectrum approach could be developed that is both effective and 
inexpensive is an important consideration, especially in low- and middle-income countries. 
One of the cost components of drug development is the cost of target identification and 
validation. However, in the Halifax Project the strategic list of targets that has been 
developed has been drawn from the open literature, so individual laboratories or nations that 
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are interested in developing a multi-component therapeutic approach can use this 
information as a starting point (i.e., as a basis for rationally selecting an array of targets).
7 Summary and conclusions
In spite of the importance of targeted therapies now used in treatment and currently in 
development, it is clear that most cancers cannot be successfully addressed solely with 
single-target therapies. The history of cancer treatment has taught us the importance of drug 
resistance, stemming ultimately from genetic heterogeneity in cancers. Our therapeutic tool 
kit now includes a large array of cytotoxic chemotherapies, molecular target drugs, 
immunotherapies and hormonal therapies. A major paradigm in cancer research, in response 
to the advances in analysis of the cancer genome, is the development of increasingly targeted 
therapies. Examples illustrating the vigor of research and development in this area are 
several targeted therapies that have received approval in 2013–2014 by the US FDA, 
including ceritinib (anaplastic lymphoma kinase inhibitor), ramucirumab (VEGFR2 
blocker), ibrutinib (Bruton’ s tyrosine kinase inhibitor), trametinib (MEK inhibitor) and 
dabrafenib (B-Raf inhibitor) [245].
At the same time there is an increasing awareness of a need to develop a therapeutic 
approach to address the genetic heterogeneity within tumors. Even within this group of 
newly approved agents, the combination of trametinib and dabrafenib was approved for joint 
use in 2014, due to the rapid (6–7 months) development of resistance to the sole use of B-
Raf inhibitors. The emergence of the concept of multiple hallmarks of cancer [27], the nine 
pathways of progression [3] the listing of 138 driver genes [6] and the recognition of the 
importance of network pharmacology [51] all attest to the importance of this issue. A recent 
review similarly suggests combining antiinflammatory and antioxidant treatment in long-
term maintenance therapy of cancer [248]. It is the contention of the Halifax Project that a 
broad-spectrum approach to cancer prophylaxis and treatment (i.e., simultaneously attacking 
many targets) is a strategic and promising response to our increasing understanding of the 
significance of genetic heterogeneity.
Although current drugs have notably increased initial responsiveness to treatment in 
comparison to traditional approaches to chemotherapy, there remain situations in which a 
broad-spectrum approach could make real contributions. Some examples include use as 
follow-up to conventional treatment; for rare cancers; for patients who do not tolerate 
conventional treatment; for early-stage disease, when aggressive treatment should be 
avoided; and in hospice and palliative care. If significant interactions with treatments can be 
avoided, it might even be possible to use such approaches in conjunction with targeted 
therapies and other treatments.
What are the implications of this broad-spectrum strategy for current clinical practice? First, 
clinicians should realize that this paper presents a developmental research program, not 
clinical guidelines. Use of uninformed selections of phytochemical or botanical extracts in 
poorly-defined clinical situations is unlikely to deliver positive results. Further, as noted 
above, concerns with interactions of natural products with conventional treatments should be 
kept in mind. That said, lifestyle therapies appear to affect multiple molecular targets and to 
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improve the health of cancer patients in a variety of ways, and integrative lifestyle 
modifications should be assessed as a health-promoting foundation for use of broad-
spectrum therapeutics [3,150]. Clinical trials are now defining beneficial impacts of natural 
products [249]. The positive implications of dietary therapies for improvement of the 
metabolic hallmarks of inflammation, dysregulated metabolism, genomic instability and 
immune system evasion should be kept in mind [250,251]. Clinicians choosing to use natural 
product supplements should attend to product quality and be familiar with advances in the 
formulation of poorly absorbed polyphenols and other phytochemicals [201–203].
The development of the broad-spectrum approach is not without cost. A primary need is 
further development of preclinical models for testing of combinatorial therapies, including 
study of the stability, pharmacodynamics and pharmacokinetics of agents comprising 
multiple phytochemicals and other molecules. While some of the targets and approaches 
recommended in these reviews are well-known and have been the subject of multiple 
reviews, others are still only promising leads and may need much better characterization 
before being adopted as constituents in such an approach. For example, among approaches, 
curcumin, genistein, resveratrol and EGCG boast a wealth of fundamental research, whereas 
other approaches such as tripterine, oleanoic acid and withaferin A will require additional 
basic research. Targets are also in need of more basic research, especially in replicative 
immortality and in dysregulated metabolism, a field in which studies of relevant targets are 
just beginning. The approaches analyzed in these areas are similarly only in the most 
preliminary stages of research. All the hallmarks, however, include targets and approaches 
that need substantial basic research. Determining how many of the suggested targets should 
be included in a broad-spectrum approach is also a question that needs substantial research. 
Supporting these areas of basic research should be an initial goal of funding efforts.
The pharmacology of mixtures of natural products is another area in which basic research is 
most relevant to the goals of this project. There is certainly a body of research on complex 
mixtures of natural products [211,215,218,219,221]. A recent study suggested that EGCG 
lowers the concentration of curcumin needed to reduce proliferation and induce apoptosis in 
uterine leiomyosarcoma cells [252]. Traditional Chinese medicine formulas have also been 
subjected to extensive pharmacological testing [253,254]. However, much remains to be 
done in quantitative optimization of formulas as well as in selection of optimal natural 
product extracts or phytochemicals. And although this effort emphasized phytochemicals, it 
is also important and relevant to study defined botanical and food extracts. Standardized 
black raspberry extract, for instance, has produced positive results in human trials on 
apoptosis, angiogenesis and several specific targets selected in the project [255]. Aged garlic 
extract [256] increased immunity in advanced cancer patients, and lyophilized strawberries 
[257] improved premalignant esophageal lesions. Defined herbal extracts such as PHY 906 
and BZL101 mentioned above have demonstrated preliminary clinical antitumor activity 
[220,221]. Stability and pharmacokinetic properties of complex mixtures are another critical 
research need, as are proper methods of quality control [258].
The development of complex natural product agents appears ripe for cross-disciplinary 
approaches as well as attention to the process of translational research. Natural products 
research, in fact, has long been nurtured most successfully in multidisciplinary and 
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collaborative working groups [259], and the teams that authored the reviews in this special 
issue were notably interdisciplinary themselves. In view of the challenges as well as the 
unique opportunities this new concept entails, scientists wishing to take part in the 
development of broad-spectrum approaches to cancer would do well to commit themselves 
to a set of new attitudes and skills. Laboratories and grant proposals have achieved success 
typically based on highly focused exploration of a small intellectual niche. The broad-
spectrum approach upends this paradigm. Building linkages with laboratories across 
campus, or even with the department down the hall, is not always encouraged in academic 
institutions. But this challenge is not insurmountable, and institutions and granting agencies 
have successfully mounted efforts that embrace, for instance, natural product development 
“from the field to the clinic” [260,261]. At the same time, integrative oncology centers 
globally employ broad-spectrum clinical approaches involving therapies ranging from 
natural products to meditation in the service of patient needs [262]. There is thus no need to 
start from absolute zero in building the cross-disciplinary alliances we project will be needed 
for this effort.
What will be needed is a core group of scientists willing to become advocates for this 
approach. Advocacy must take place within academic institutions, as institutional silos, 
perhaps reluctantly, open their doors to collaboration. Institutional review boards and grant 
offices may need education in the concept of the broad-spectrum approach. Advocacy must 
take place at higher levels as well. National funding agencies and charitable foundations that 
currently support cancer research need to heed these recommendations and shift quickly to 
embrace the rationale for this interdisciplinary team-based approach. Grant review 
committees may need to confront established interests promoting competing studies with 
more familiar narrow aims. Creativity in funding initial research efforts will be needed. 
International agencies interested in addressing the growth of cancer in low to middle income 
countries might be convinced that broad-spectrum approaches could result in lower-cost and 
often more culturally acceptable therapeutic tools for these areas.
Now is the time to begin the work of advocating for broad-spectrum therapeutic approaches 
in cancer. Scientists need to seize the opportunities provided by the unique information 
provided in this special issue to expand their acquaintance with this model - and perhaps 
with the scientists themselves who are already involved in this effort. Scientists and 
clinicians alike should become advocates to their institutions, to funding sources and to the 
wider public. This dimension of cancer biology and therapy has too much potential to allow 
it to languish. At the same time, clinical challenges mount, despite the emergence of new 
targeted therapies. We look forward to seeing concentrated energy and intellect focused on 
this new approach, and to seeing it yield significant therapeutic benefits in the future.
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Figure 1. 
Diagrammatic representation of removal of susceptible cells by a targeted cancer therapy 
resulting in disease remission, which leaves genetically heterogeneous resistant cells to 
proliferate, resulting in relapse.
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Figure 2. 
Hallmarks of cancer, sequenced roughly in the order in which these capabilities are acquired 
by most cancers, as portrayed in the graphical representation of tumor evolution.
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Table 1
Prioritized targets with summary of information from cross-validation tables.
Hallmark1,2
Target (action on
target) Contrary Controversial Complementary
None
known
AP, RI, TPI Akt (inhbit) 0 0 11 0
SPS Androgen receptor signaling (suppress) 0 2 8 1
TIM AP-1 (inhibit) 1 RI 0 7 3
EAG ARID1A (activate) 1 TIM 0 5 5
AP Bcl-2 (inhibit) 0 1 9 1
RI CDK 1/2/5/9 (inhibit) 1 TME 0 9 1
RI CDK 4/6 (inhibit) 1 GI 1 8 1
SPS Cell cycle (CDKs/cyclins) (attenuate) 2 IS, TIM 0 9 0
GI Centrosome clustering (block) 0 0 8 3
TME Cholesterol metabolites (inhibit) 0 0 7 4
TME Cholesterol synthesis (inhibit) 0 1 8 2
TPI COX-2 (inhibit) 1 AN 0 10 0
TPI CXC chemokine (inhibit) 0 3 5 3
AN Disturbed circadian rhythms (normalize) 0 2 9 0
GI DNA damage (prevent) 1 TPI 3 5 2
GI DNA repair (enhance) 1 TPI 3 5 2
EAG, TIM E-cadherin (restore) 1 AN 4 4 2
EAG E2F (inactivate) 1 TME 0 7 3
AP EGFR (inhibit) 0 0 10 1
AN Elevated interstitial fluid pressure (reduce) 0 0 9 2
TME Endoglin (inhibit) 0 1 5 5
AN Endothelial cell migration/tip cell formation (inhibit) 0 0 7 4
AP Enox (inhibit) (AP) 0 0 5 6
SPS ER signaling (suppress) 1 TIM 3 7 0
EAG ER stress (induce) 2 AN, TIM 1 7 1
TIM FAK signaling (inhibit) 0 0 9 2
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Hallmark1,2
Target (action on
target) Contrary Controversial Complementary
None
known
TME Fibrosis (inhibit) 0 0 6 5
EAG Growth differentiation factor 15 (induce) 1 GI 0 5 5
SPS HIF-1 signaling (inhibit) 0 0 9 2
AP Hsp90 (inhibit) (AP) 1 TIM 0 8 2
RI hTERT (inhibit) 0 1 8 2
AN Hypoxia (reduce) 0 1 10 0
TME IDO (inhibit) 0 1 7 3
EAG, SPS IGF-1R (inhibit) 0 0 9 2
IE IL-12 (induce) 1 AP 0 5 5
TME IL-6 (inhibit) 0 3 7 1
TPI iNOS (block) 1 AN 1 6 3
TME JAK (inhibit) 0 0 10 1
AN Lymphangiogenesis (impede) 0 1 4 6
TME M2 macrophage conversion (inhibit) 0 0 7 4
IE Macrophages (activate) 2 SPS, TIM 2 3 4
AP Mcl-1 (inhibit) 0 0 10 1
TPI MIF (block) 0 0 9 2
TIM MMP-9 (suppress) 0 1 7 3
RI mTOR (inhibit) 0 2 8 1
SPS, TIM, TPI NF-KB signaling (inhibit) 0 2 8 1
IE NK cell activity (promote) 0 0 7 4
EAG NOTCH (block) 1 AN 0 8 2
AP Nuclear exporter CRM1 (inhibit) 0 0 6 5
RI PI3K (inhibit) 0 0 11 0
EAG, SPS, TIM PI3K/Akt signaling (inhibit) 0 0 11 0
AN Poor perfusion (improve) 0 1 7 3
AP Proteasome (inhibit) 0 0 10 1
TME ROS (inhibit) 0 2 7 2
AN Structural abnormalities of vessel walls (inhibit) 0 0 7 4
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Hallmark1,2
Target (action on
target) Contrary Controversial Complementary
None
known
GI Target deficient DNA repair 1 TPI 2 5 3
GI, RI Telomerase (inhibit) 0 0 10 1
TIM TGF-Ś(inhibit) 1 RI 2 7 1
IE Th1 response (promote) 1 TPI 0 5 5
TIM Tight junctions (promote) 1 AN 0 6 4
TPI TNF-ř(block) 1 IE 1 8 1
IE Treg lymphocytes (inhibit) 0 1 6 4
AP Tumor autophagy (activate) 1 TPI 4 4 2
AN Tumor cell metabolism/acidosis (normalize) 0 0 9 2
AP Tumor necrosis (activate) 2 AN, TME 3 5 1
AN Tumor-promoting fibro-blasts (deactivate) 0 0 9 2
AN Tumor-promoting inflammation (suppress) 0 0 7 4
TIM Urokinase plasminogen activator (suppress) 1 RI 0 7 3
TME VEGF (inhibit) 0 3 8 0
EAG Wildtype p53 (upregulate) 0 0 10 1
SPS Wnt (B-catenin) (inhibit) 0 3 7 1
EAG YAP/TEAD activity (inhibit) 0 0 6 5
TIM Ś-catenin/ZEB1 (inactivate) 0 0 7 4
IE śŜ T-cell activity (promote) 2 TPI, AN 0 4 5
Totals: 32 62 543 177
Percentages: 3.93% 7.62% 66.71% 21.74%
1
For each target, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary relationships, no 
known relationships and controversial relationships. For targets that have contrary relationships, the conflicted hallmark(s) are shown. Totals and percentages of each type of relationship are shown at the 
end of the table.
2AN = Angiogenesis, AP = Resistance to Apoptosis, DM = Dysregulated Metabolism, EAG = Evasion of Anti-Growth Signaling, GI = Genomic Instability, IE = Immune Evasion, RI = Replicative 
Immortality, SPS = Sustained Proliferative Signaling, TIM = Tissue Invasion and Metastasis, TME = Tumor Microenvironment, TPI = Tumor Promoting Inflammation.
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Table 2
Prioritized approaches with summary of information from cross-validation tables.
Hallmarks1,2 Approaches
Contrary,
Conflicted
Hallmarks Controversial Complementary
None
Known
DM 3-bromopyruvate * 0 0 7 4
TIM 5,6-dihydro-4H-pyrrolo[1,2-b]-pyrrazoles * 0 0 2 9
TPI Anthocyanins 0 0 9 2
IE Astaxanthin 0 0 7 4
IE Astragalus membranaceus polysaccharide 1 AN 0 6 4
TME Berberine 1 IE 0 9 1
DM BPTES * 0 0 5 6
GI Carotenoids 0 1 10 0
TIM Cordycepin 0 0 8 3
AN, EAG, RI, SPS, TME, TPI Curcumin 0 0 11 0
EAG Deguelin 0 0 7 4
TME Desoxyrhapontigenin 0 0 2 9
DM Dichloroacetate * 0 0 7 4
RI Dinacicilib * 0 0 6 5
AN, AP, EAG, RI, TME, TPI EGCG 0 0 11 0
TIM Eicosapentaenoic acid 0 0 8 3
AN Enterolactone 0 0 7 4
DM FX11 * 1 GI 0 2 8
TIM Gamma linolenic acid 0 0 7 4
TIM Ganoderic acids 0 0 7 4
IE Ganoderma lucidum polysaccharide 0 0 9 2
EAG, RI, SPS, TME, TPI Genistein 0 5 6 0
AP Gossypol 0 0 9 2
TIM Grifolin 0 0 6 5
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Hallmarks1,2 Approaches
Contrary,
Conflicted
Hallmarks Controversial Complementary
None
Known
DM GW5074* 0 1 3 7
DM Hexachlorophene * 0 0 6 5
IE HS-1793 (polyphenol resveratrol analogue)* 0 0 5 6
RI Imetelstat* 0 1 4 6
GI Isothiocyanate 0 0 10 1
AN Kaempferol 0 0 7 4
IE Lentinus edodes polysaccharide 0 0 8 3
EAG Luteolin 0 0 9 2
TPI Lycopene 0 0 8 3
AN Melatonin 0 0 10 1
DM Metformin* 0 1 10 0
TME Naringenin 0 2 6 3
AN Oleanoic acid 0 0 10 1
TME Onionin A 0 0 1 10
TIM Pachymic acid 0 0 6 5
RI Palbociclib * 1 TIM 0 4 6
GI PARP inhibitor* 0 0 9 2
RI Perillyl alcohol 0 0 10 1
TME Piperine 1 IE 0 7 3
DM PK15 * 0 0 6 5
TIM Polysaccharide (G. lucidum) 0 1 8 2
AN, DM, EAG, GI, SPS, TME, TPI Resveratrol 0 2 9 0
GI Selenium 1 TPI 2 6 2
AP Selinexor * 0 0 3 8
AN, TIM Silibinin 0 0 11 0
DM TEPP-46 * 0 0 3 8
IE Trametes versicolor polysaccharide-k 0 0 3 8
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Hallmarks1,2 Approaches
Contrary,
Conflicted
Hallmarks Controversial Complementary
None
Known
AN Tripterine 0 0 5 6
AP Triptolide 1 IE 0 9 1
AP UMI-77 * 0 0 5 6
GI Vitamin B 0 2 3 6
GI Vitamin D 0 0 10 1
AN, EAG Withaferin A 0 0 9 2
TME Zerumbone 0 0 6 5
TIM Ś-(1–6)-D-glucan (A. blazei) 0 0 6 5
Totals: 7 18 403 221
Percentages: 1.08% 2.77% 62.10% 34.05%
1
For each approach, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary relationships, no 
known relationships and controversial relationships. For approaches that have contrary relationships, the conflicted hallmark(s) are shown. Totals and percentages of each type of relationship are shown at 
the end of the table. Approaches are natural products except for those noted by asterisks.
2AN = Angiogenesis, AP = Resistance to Apoptosis, DM = Dysregulated Metabolism, EAG = Evasion of Anti-Growth Signaling, GI = Genomic Instability, IE = Immune Evasion, RI = Replicative 
Immortality, SPS = Sustained Proliferative Signaling, TIM = Tissue Invasion and Metastasis, TME = Tumor Microenvironment, TPI = Tumor Promoting Inflammation.
*
Targeted therapy, synthetic compound or natural product analog/derivative
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Table 3
Numbers of targets and therapeutic approaches for each hallmark with the following relationships: complementary relationship, contrary relationship, no 
known relationship and controversial relationship. Based on cross-validation tables.
Type of
relationship
Genomic
Instability
Sustained
Proliferative
Signaling
Tumor-
promoting
Inflammation
Evasion of
Anti-
growth
Signaling
Resistance
to Apoptosis
Replicative
Immortality
Deregulated
Metabolism
Immune
System
Evasion
Angiogenesis Tissue
Invasion
and
Metastasis
Tumor
Microenvironment
Targets
Complementary 30 52 53 53 62 34 55 44 44 65 61
Contrary 2 1 6 0 1 0 0 2 9 5 3
None known 52 24 18 20 13 37 23 34 15 7 9
Controversial 1 5 6 7 4 12 5 4 12 3 7
Therapeutic Approaches
Complementary 35 51 44 50 62 37 42 22 40 60 64
Contrary 0 0 1 0 0 0 0 3 2 1 0
None known 39 20 26 17 11 37 27 39 23 11 9
Controversial 1 8 5 5 1 1 6 12 7 0 0
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